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CHAPTER ONE
GENERAL INTRODUCTION
Human herpesviruses. Indication of herpesviruses causing human disease
dates back to the early days of medicine when Hippocrates used the Greek word
“herpes” to describe lesions that appeared to creep across the skin. The term herpes,
however, was used ubiquitously to define several skin conditions. It was Vidal that
proved a herpesvirus, herpes simplex virus (HSV), is the infectious agent responsible by
conducting human-to-human transmission studies (1). Future experiments by Andrews
and Carmichael showed that HSV could cause recurrent infections in adults with
neutralizing antibodies, but it was Burnet and Williams that recognized HSV can
establish a lifelong latent infection that can still cause herpetic lesions in the presence of
external stimuli (2).
All viruses classified under the Herpesviridae family have similar virion
structures. Each virion is composed of a double stranded DNA genome packaged inside
an icosahedral capsid. Surrounding the capsid is an amorphous proteinacious coat
labeled the tegument layer that forms a scaffold between the capsid and the outer lipid
envelope (Fig. 1). There are over 200 viruses that belong to the Herpesviridae family
with only 8 known to primarily infect humans (3). The human herpesviruses belong to
three

different

subfamilies

(Alphaherpesvirinae,

Betaherpesvirinae,

and

Gammaherpesvirina) based on biological properties. The Alphaherpesvirinae consist of
HSV 1 and 2, and varicella-zoster virus (VZV), with a broad host range and short
replication cycle. The Betaherpesvirinae include human cytomegalovirus (HCMV),
human herpesvirus 6 (type A and B), and human herpesvirus 7, which have a narrow
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host range and a long replication cycle. The last subfamily Gammaherpesvirinae, are
composed of Epstein-Barr virus and Kaposi's sarcoma virus that have the most
restricted host range.
Although the rate of the replication varies between the subfamilies, they share a
common life cycle. Infection is initiated upon attachment of viral glycoproteins to species
specific cellular receptors. Fusion of the viral envelope with the host membrane at the
plasma membrane or inside endocytic vesicles mediates entry of the capsid and the
release of tegument proteins into the cytoplasm (4, 5). The tegument proteins modulate
host cell immune responses, regulate host cell protein synthesis, and facilitate the
transport of the nucleocapsid to the nucleus. Docking of the nucleocapsid to the nuclear
pore releases viral DNA into the nucleus where tegument proteins trans-activate viral
gene expression. This initiates the lytic gene cascade consisting of three major kinetic
classes (immediate early, early, and late) which lead to the production of viral particles.
Released infectious viral progeny are capable of establishing a life-long latent infection,
which can be reactivated in response to various stimuli.
HCMV clinical relevance. HCMV is an opportunistic pathogen that has spread
worldwide. Primary infections occur through contact with infected blood and urine, or
mucosal secretions. The seroprevalence rate in the United States hovers around 50%,
but rates are significantly higher in under developed countries (6, 7). Infection of healthy
individuals is usually mild and self-limiting, yet results in a life-long latent infection with
periodic episodes of reactivation.
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Primary infection or reactivation of HCMV presents a concern to the
immunocompromised, such as AIDS patients and transplant recipients. The assault on
CD4 lymphocytes by HIV leaves the immune system depleted and allows HCMV
proliferation and dissemination, leading to retinitis, gastrointestinal disease, and
pneumonitis (8). HCMV retinitis once accounted for 90% of AIDS related vision loss until
the development of highly effective antiretroviral and anti-CMV therapies (9, 10).
Unfortunately, low income countries have limited access to these drugs which leaves
AIDS patients at risk for acquiring HCMV retinitis (11). Also at risk of HCMV disease are
solid organ and hematopoietic stem cell transplant patients as a result of life-long
immunosuppressive drug regimens. Infection and invasion of HCMV into tissues can
cause pneumonia, hepatitis, encephalitis, and even death. Fortunately, ganciclovir,
high-dose acyclovir, and valacyclovir treatment have been shown to prevent early onset
HCMV disease in hematopoietic stem cell transplants (12-15). Delayed onset HCMV
disease still presents a major problem for clinicians who have turned to monitoring
patients long term through pp65 antigenemia and PCR testing (12, 16).
HCMV infection is also a concern for pregnant mothers who can vertically
transmit the virus to their child during pregnancy or childbirth. In developed countries,
HCMV is the most common viral congenital infection with 0.2% to 2.5% of newborns
being affected (17). Infected children can be symptomatic or asymptomatic at birth, but
all are at risk of developing severe neurological abnormalities that cause mental
retardation, microcephaly, seizures, and hearing loss. In fact, HCMV is the leading
cause of non-genetic sensorineural hearing loss among infants (7, 18). Anti-viral
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treatment is recommended and effective in symptomatic congenital HCMV cases, but
an HCMV vaccine would address asymptomatic and in utero infections (19).
HCMV virion structure and genome. HCMV is the largest known human
herpesvirus. The diameter of a single virion ranges from 150- 200 nm, which houses a
linear double stranded DNA (230 kbp). The genome contains a unique long (UL) and a
unique short region (US), flanked by sets of internal repeats (TRL/IRL and IRS/TRS
respectively). Inversion of the UL and US regions allows up to four different isoforms of
the HCMV genome. The coding capacity of the laboratory strain AD169 genome is
around 190 translated open reading frames (ORFs) which all show high similarity to
clinical isolates (20, 21). However, the total number of translated ORFs can be as high
as 750 when including small codons (<80) and alternative transcript start, stop and
splice sites, thus demonstrating the complexity of HCMV infection (22).
HCMV attachment and entry. The broad cell tropism of HCMV is an essential
component to multi-organ spread and disease. Clinical strains of HCMV have the ability
to infect epithelial cells, endothelial cells, fibroblasts, smooth muscle cells, monocytes,
and macrophages. The proteoglycan heparin sulfate is found on the all of these cells
and is the primary site of attachment for HCMV glycoproteins gB and gM/gN (23). Other
cell surface receptors have been proposed (i.e. EGFR and PDGFR), however,
neutralizing antibody against these ligands proved unsuccessful at preventing entry,
alluding to the possibility of alternative entry pathways (24, 25). Integrins, specifically
α2β1, α6β1, and αvβ3, have also been considered attachment sites. Studies using antiintegrin antibodies inhibited entry, yet binding still occurred, suggesting integrins are
involved in virus-cell membrane fusion (26). The location of the fusion step differs
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depending on cell type. In fibroblasts, fusion takes place at the outer cell membrane,
which involves the viral glycoproteins gH and gL (5, 27), but in epithelial and endothelial
cells, gH/gL forms a complex with proteins pUL128, pUL130 and pUL131 to initiate a pH
dependent fusion that occurs after endocytosis of the virus particle (4).
Following fusion, viral tegument proteins are released into the cytoplasm of the
cell to facilitate a productive infection. Some include viral proteins that can counteract
the host antiviral response. TRS1 and IRS1 prevent the phosphorylation of eukaryotic
translation initiation factor eIF-2alpha and the activation of RNase L, which blocks
cellular protein synthesis (28). Another viral mechanism of immune evasion is inhibiting
antigen presentation. One of the most abundant tegument proteins, pp65, blocks the
antigen processing of IE2 to avoid cytotoxic killing by CD8+ T cells (29), and degrade
HLA class II molecules to prevent recognition by CD4+ T cells (30). Other capsid
associated tegument proteins are responsible for mediating the transport of the
nucleocapsid to the nuclear pore via microtubules. Docking of the capsid initiates
release of the viral genome into the host cell nucleus.
HCMV gene expression and replication. Once the HCMV genome enters the
nucleus, it circularizes and localizes to nuclear domain 10 sites, where tegument
proteins initiate the lytic gene cascade. Although transfection of viral DNA alone results
in productive infection, infectivity substantially increases in the presence of viral
transactivators, such as pp71 and pUL35 (31). The association between pp71 and
pUL35 act cooperatively to stimulate the major immediate early promoter and begin lytic
gene expression (32). The primary products of the major immediate early promoter are
immediate early genes IE1-p72 and IE2-p86. These proteins are involved in a variety of
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functions, including evasion of host innate immunity, regulation of the cell cycle, and
transactivation of viral and host genes (33-35). Although only IE2 is essential for
replication (36), both IE1 and IE2 work synergistically with other viral and cellular
components to drive early gene expression (37, 38).
Early genes are the second kinetic class of genes expressed during a lytic
infection and are required for viral DNA replication. HCMV DNA synthesis follows the
assembly of viral and cellular proteins at the origin of lytic replication, termed oriLyt. To
date, 11 viral genes are associated with oriLyt replication: UL44 (DNA processivity
factor), UL54 (DNA polymerase), UL57 (single stranded-DNA-binding protein), UL70
(primase), UL84 (replication initiator protein), UL102 (primase-associated factor), UL105
(helicase), IRS1/TRS1, and UL36–38, UL112/113, and IE2 (39-41). Localization of
UL84 and IE2 to replication centers initiates oriLyt-dependent replication in fibroblasts
(41). Viral DNA is replicated via a rolling circle mechanism that generates concatemeric
HCMV genomes. Concurrent with viral DNA replication is the expression of late genes.
HCMV assembly and egress. The production of late proteins leads to procapsid
assembly. These preformed capsids recognize and target the concatemeric viral DNA
for encapsidation. Cleavage of the concatemer packages a single HCMV genome per
capsid. The formation of the nucleocapsid is followed by an envelopment and deenvelopment process to exit the nucleus (42). At the inner nuclear membrane, primary
envelopment is triggered by the pUL97 mediated phosphorylation of the nuclear egress
complex, subunits pUL50 and pUL53 (43). Subsequent de-envelopment occurs at the
outer nuclear membrane and releases the nucleocapsid into the cytoplasm.
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While some tegument proteins are added to the nucleocapsid during nuclear
egress, most are acquired in transit towards sites of secondary envelopment.
Envelopment occurs at specialized, HCMV induced, cytoplasmic vesicles that contain
markers for trans-Golgi, multi vesicular bodies, and endosomes (44-46). Budding of
particles into these vesicles is followed by exocytosis, in which the mature virion is
released from the cell. The cytoplasmic process of assembly, envelopment, and egress
all occur inside the HCMV induced cytoplasmic virion assembly complex (cVAC).
Cytoplasmic virion assembly complex. A hallmark of HCMV infection is
nuclear and cytoplasmic enlargement or cytomegaly. Following 3 to 4 days post
infection, the host cell nucleus takes on a kidney bean-like shape that partially wraps
around a perinuclear structure termed the cVAC. This structure is the final site of virion
maturation and necessary for efficient virion production. The formation of the cVAC
involves the structural rearrangement of multiple cellular organelles. The interior
compartment consists of a microtubule organizing center (MTOC) and EEA1 positive
endosomes that are encircled by a ring of intertwined Golgi and trans-Golgi components
(47). Microtubules emanating from the MTOC are thought to be responsible for the
trafficking of virions through the cVAC (Fig. 2). Also, Rab GTPases and endosomal
sorting complex required for transport (ESCRT) gather at the cVAC and are implicated
in virion maturation; perturbing components of either pathway results in decreased viral
titers (48-50). Rab proteins are master regulators that control the flow of membrane
traffic and target viral proteins to their appropriate destination. ESCRT machinery
perform membrane bending and scissioning events that may contribute to the budding
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of nucleocapsids into endocytic vesicles (The role of ESCRT proteins is described
further in the following section).
In addition to cellular proteins, many viral tegument proteins and glycoproteins
heavily localize to the cVAC for virion production (51, 52). A mature HCMV virion is
composed of 70 different viral proteins with at least 32 being tegument proteins (53, 54).
The process of virion assembly is incompletely understood, but requires, in part,
tegument proteins pUL32 (pp150), pUL99 (pp28), pUL94, pUL71 and pUL103 (55-58).
The second most abundant tegument protein, pUL32, serves a multifunctional
role during infection. At early times, pUL32 localizes to the nucleus and is tightly bound
to capsids (59-61). Initial studies with pUL32 antisense mRNA appeared to block the
translocation of nucleocapsids to the cytoplasm, indicating a role in nuclear egress (62).
In support of these knockdown studies, a UL32 deletion virus grown on complementing
cells showed an accumulation of viral DNA in the cytoplasm, but few discernable
nucleocapsids (63). In addition, mutagenizing pUL32 conserved region 1 (CR1) or CR2
perturbed cVAC organization and virion maturation (63). This data indicates a dual role
of pUL32 in stabilizing nucleocapsids and virion assembly.
The UL99 protein is a highly conserved myristoylated and phosphorylated protein
(64). The deletion or mislocalization of HCMV pUL99 (pp28) causes a defect in viral
replication and irregular Golgi structures (56, 64, 65). Interesting, only the N-terminal 50
amino acids that carry the multimerization, myristoylation, and pUL94 binding domain
are necessary for virion production (64, 66). Disruption of a single cysteine residue at
position 250 of pUL94, or the deletion of pUL99 residues 37-39 disrupts the pUL94-
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pUL99 interaction, which causes the dispersal of both proteins from the cVAC (55, 67).
The proper localization of pUL94 and pUL99 is essential for virus production.
Equally as important in the process of envelopment is pUL71. In the absence of
pUL71, the cVAC contains abnormally large cytoplasmic inclusions labeled with LAMP1
and CD63, markers for late endosomes and multivesicular bodies (68, 69). Virus
particles located at these enlarged vesicles have delayed envelopment and thus
impaired release. In transfection experiments, pUL71 binds to pUL103 with localization
of pUL103 dependent on the pUL71interaction (70). Interestingly, a pUL103 deletion
mutant also shows nucleocapsids suspended in the process of secondary envelopment
and lower viral titers (58). These results suggest that pUL71 and pUL103 form a protein
complex that functions during the final stages of virion maturation.
The process of HCMV assembly and egress in the cVAC is highly complex and
requires the concerted effort of viral and cellular proteins. A recent study shows viral
proteins are able to subvert the antiviral function of interferon-induced transmembrane
proteins (IFITMs) for cVAC formation and efficient virus production (71). Also, host
proteins contribute to the proper localization of viral proteins, as in how Rab6 interacts
with and traffics pUL32 to the cVAC during infection (50). The functions of these viral
and cellular interactions are only beginning to be uncovered. Understanding the
interplay between viral and cellular proteins in the cVAC will provide further insight to
late stages of HCMV infection, as well as basic cell biology.
ESCRT machinery. The process of subverting host cell machinery for virion
production is a common theme among multiple viruses. Although not much is known
about HCMV secondary envelopment, there is evidence that HCMV obtains its
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envelope in endocytic compartments. (i) In HCMV infected cells incubated with
horseradish peroxidase (HRP), virions and HRP were present in the same compartment
(44). (ii) Purified infectious HCMV virions contain CD63, a multivesicular body marker
(45). (iii) Dominant negative ESCRT components, CHMP1A and VPS4A reduce
infectious yield (48).
The formation of these endocytic vesicles is mediated by ESCRT machinery (Fig.
3). The ESCRT pathway is initiated by ESCRT-0 subunits binding phosphatidylinositol
3-phosphate, ubiquitinated proteins, and TSG101 of ESCRT-I. Sequential recruitment of
ESCRT-I and ESCRT-II subunits concentrates ubiquitinated cargo to begin the
membrane invagination process. Activation of the ESCRT-III complex completes the
membrane scissioning and releases the newly formed vesicle. HCMV may use all or a
combination of these players during secondary envelopment.
In retroviruses, ESCRT machinery is recruited to sites of envelopment by signal
motifs found on viral proteins. These signals are often the same or similar to those
present on host cell proteins, and are termed “late” or “L” domains: P(T/S)AP, PPXY,
and YPXnL. The P(T/S)AP late domain is used to recruit TSG101, and thus ESCRT-I, to
sites of virion envelopment (72, 73). The PPXY motif binds WW domains of NEDD4
family members that target specific proteins for ubiquitination (74). YPXnL late domains
in retroviruses bind the V domain of ALG-2 interacting protein X (ALIX) to facilitate viral
budding at the cell membrane (75-77).
Although ESCRT machinery is critical for retrovirus budding, evidence of ESCRT
involvement during HCMV envelopment is conflicting. siRNA knockdown of TSG101,
ALIX, Vps4A and Vps4B in retinal pigment epithelial cells had either no effect or a slight
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increase in HCMV virion production (78).

However, dominant negative versions of

CHMP1A and VPS4A in human fibroblasts reduced infectious yields by 100-fold at 6 dpi
indicating the necessity of ESCRT-III in virion production (48). In the same study,
CHMP1A and Vps4A localized in or around the cVAC, but how these ESCRT-III
components are recruited to sites of HCMV envelopment remains a mystery. Sequence
analysis of HCMV tegument and glycoproteins revealed numerous late domains. One
P(T/S)AP motif in pUL32, two PPXY motifs in gB and pUL48, and 7 HCMV proteins
(including pUL103) with ALIX binding domains YPXnL. With this redundancy and
multiple pathways leading to ESCRT-III recruitment (ESCRT-II, NEDD4, ALIX, or an
unidentified viral protein), identification of functional late domains in HCMV may provide
insight to the process of secondary envelopment.
UL103. The HCMV UL103 gene encodes a tegument protein that is conserved
among all human herpesviruses. Early work on the alphaherpesvirus homolog UL7 has
shed light on the process of UL103 gene transcription. The UL7 gene is located on the
unique long region of the genome and overlaps the upstream UL6 gene (homolog of
HCMV UL104) at its 5’ end. Analysis of the UL7 and UL6 transcript reveals a shared
poly A tail with both genes being transcribed simultaneously in herpes simplex virus 1
(HSV-1) and psuedorabies virus 1 (PrV-1) (79, 80). The UL6 gene product is essential
in forming the entry portal for packaging viral DNA in preformed capsids (81), while the
UL7 gene is a nonessential structural protein with late transcription kinetics (79, 80, 82).
The HCMV UL103 gene is similar to its alphaherpesvirus counterpart (UL7) in a
variety of ways. (i) The UL103 gene shares 53 base pairs with the neighboring UL104
gene, indicating cotranscription. (ii) Expression of UL103 is regulated as a late gene
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with the protein incorporated into virions ((54, 83)). (iii) Disruption or deletion of the
UL103 ORF causes smaller plaque size, decreased viral titers, and defects in virion
release (58, 82, 84-87). (iv) pUL103 and the HSV-1 homolog accumulate in the
cytoplasm at late times post infection and colocalize with cytoplasmic membranes (58,
88). (v) The localization of pUL103 is dependent on its interaction with pUL71, which is
also evident in the HSV-1 homologs pUL7 and pUL51 (70, 88). However, some
properties of pUL103 are HCMV specific. For instance, HCMV produces sacs of
enveloped tegument proteins called dense bodies during infection. The formation of
dense bodies is independent of virion assembly, but the release of both particles is
controlled by pUL103 (58). The properties of the highly conserved HCMV pUL103 have
been explored extensively, yet the function of pUL103 during infection has yet to be
elucidated.
Insight to the possible functions of pUL103 can be gathered from previous
studies on pUL7. For instance, the UL7 protein of HSV-2 appears in the nucleus and is
weakly associated with A, B, and C capsids (89). Although HCMV pUL103 has not been
identified as nuclear, it does contain a conserved G-F-x(8)-E-D-x-V-x(12)-R domain with
similarity to DNA topoisomerase III of fission yeast, hinting to a possible role in
packaging or DNA transcription. Also, co-immunoprecipitation of HSV-1 pUL7 pulled
down cellular mitochondrial proteins ANT2 and ANT4 (82). The biological significance of
these interactions was not pursued, but could be involved in regulating mitochondrial
function to facilitate a productive infection.
This work. Currently, there are only four drugs approved for HCMV treatment,
but all target steps of DNA replication. Because of this, resistance to these types of
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drugs is increasing. An alternative approach is to prevent cVAC assembly, and thus
inhibit viral production. However, the viral proteins involved in cVAC formation have yet
to be characterized.
The focus of this work was to identify individual viral proteins that control cVAC
biogenesis. The formation of the cVAC follows viral DNA synthesis, which implies a
connection to late genes. Although this does not exclude immediate early and early
gene involvement, it provides an initial starting point for viral genes to pursue. Also, a
fully formed cVAC is critical for efficient virus production, so we chose to focus on late
genes that display a growth defect when the ORF is disrupted. This led to the screening
of 26 genes, from which three viral proteins (pUL48, pUL94, and pUL103) were
identified as important for cVAC biogenesis. These three viral proteins as well as their
interacting partners, whether they are viral or cellular proteins, can provide potential
targets for developing anti-viral drugs.
To further understand the functions of pUL103, we conducted a dual method
approach of affinity purification followed by mass spectrometry to elucidate pUL103
binding partners. By using two different methods and enriching for interactions identified
by both, we were able to reduce the amount of false positives while also improving the
likelihood of a true interaction. We identified and verified pUL103 interactions with
multiple nuclear viral proteins (IE2, pUL34, and pUL44), an antiviral (IFI16) and ESCRT
associated protein (ALIX). These interaction partners revealed a nuclear association of
pUL103, as well as possible functions in the antiviral response and ESCRT machinery
recruitment, suggesting a multifaceted role of pUL103 during HCMV infection.
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Figure 1. Herpesvirus virion structure
Used with permission from http://www.twiv.tv/virus-structure/
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Figure 2. Schematic representation of the cVAC and proposed path of virion egress
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Figure 3. Formation of intraluminal vesicles by ESCRT machinery; the proposed
pathway for HCMV virion envelopment
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CHAPTER TWO
VERIFYING THE ROLES OF pUL48 AND pUL103 IN CVAV BIOGENESIS
This chapter is written as published in the Journal of Virology, August 2014.
Subhendu Das PhD conducted the siRNA screen to identify viral candidates involved in
assembly complex biogenesis (figures 3-5). I constructed and characterized two
recombinant viruses to verify the siRNA screen results (figures 6-13).
Introduction
Herpesvirus virion assembly is a complex process (reviewed in (90, 91)).

A

portion takes place in the nucleus, which is the site of viral DNA replication, formation of
and filling the nucleocapsid with viral DNA, and acquisition of the initial tegument layer.
The major pathway of virion maturation involves the nascent capsid budding through the
inner nuclear membrane into the lumen of the nuclear membrane, thus acquiring the
primary envelope. Subsequently, the virion “infects” the cytoplasm through the outer
nuclear membrane, leading to loss of the primary envelope. Tegument components are
added during movement through the cytoplasm to a vesicle into which the particle buds,
acquiring its mature envelope. The vesicle housing the virion is transported to the cell
surface where the virion is released in an exocytic process.
Human cytomegalovirus (HCMV) induces cytopathic effects that include
cytoplasmic and nuclear enlargement, and development of characteristic cytomegalic
nuclear and cytoplasmic inclusions (reviewed in (92)). The large cytoplasmic inclusion
corresponds to the cytoplasmic virion assembly complex (cVAC) (51). cVAC are large
cylindrical structures that are present one per infected cell, even in multinucleate
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syncytia. Nuclei take on a kidney-like (reniform) shape as they bend partially around
the cVAC (93). Electron microscopic evidence indicates that the cVAC is the site of
final tegumentation and envelope acquisition (44, 94, 95).

Viral tegument proteins,

envelope proteins, and some non-structural proteins localize to the cVAC, and
cytoskeletal filaments appear to radiate from a microtubule organizing center in the
cVAC (46, 51, 96, 97). The cVAC is relatively devoid of endoplasmic reticulum (ER)
markers. The ER-to-Golgi intermediate compartment (ERGIC), Golgi apparatus, and
trans-Golgi network (TGN) form a cylindrical ring that outlines the cVAC (47, 51, 96).
Tooze et al. (44) treated cells with soluble horseradish peroxidase, which is taken
up by recycling endosomes, and found its reaction product of oxidized diaminobenzidine
in cytoplasmic vesicles that contained what appeared to be tegumented and enveloped
HCMV virions, providing direct evidence that the virion exit vesicle is related to recycling
endosomes.

Consistent with this, we and others found that molecular markers of

recycling endosomes (early endosome antigen 1 (EEA1) and Rab11) stain vesicles that
cluster at the center of the cVAC (45, 47, 58, 96, 98). Exactly how virions mature in the
cVAC remains a mystery, and it has not been demonstrated whether a fully formed
cVAC is necessary for efficient virion production. Although structures morphologically
similar to the HCMV cVAC have not been described for other herpesviruses, a recent
study found that herpes simplex virus 1 virions acquire their envelope at tubular
structures that share many properties with recycling endosomes (99).
Although the full set of viral regulators of cVAC biogenesis has not been
identified, some things are known: (i) cVAC do not form in the absence of viral DNA
synthesis ((97) and our unpublished observations), indicating that its formation is
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dependent on expression of one or more viral late genes; gene(s) from an earlier kinetic
class may also be involved. (ii) Treatment of cells with nocodazole, which
depolymerizes microtubules, leads to rapidly reversible cVAC disruption (100). While
microtubules are important (even essential) components of the cVAC, they are not likely
to be regulators of cVAC biogenesis. (iii) The kinase activity of pUL97 is required for
formation of perinuclear complexes that correspond to cVAC and for efficient production
of infectious virions, but UL97 activity alone is insufficient for cVAC development (97,
101, 102). (iv) Although not examined in detail, images in papers describing some
HCMV mutants that have defects at late stages of virion assembly are consistent with at
least some features of cVAC-like structures forming in the absence of UL32, UL91,
UL96, UL99 (56, 57, 69, 103). (v) In contrast, insertion of a stop codon into the UL103
open reading frame resulted in the absence of well-formed Golgi rings, but the recycling
endosomal compartment was not studied (58).

In addition, in cells infected with a

pUL71-deficient virus, viral proteins that normally associate with the cVAC are
mislocalized (69). (vi) cVAC form in cells infected with highly passaged laboratory
strains of HCMV that lack some genes present in wild type viruses (preceding
references), as well as after infection with a low passage virus that encodes a nearly
complete complement of HCMV genes (104). Interestingly, an HCMV locus spanning
UL133 to UL138 is required for cVAC development in human microvascular endothelial
cells, but not in embryonic lung fibroblasts (104), indicating that cell-specific viral factors
can be involved. (vii) In addition to protein regulators of cVAC biogenesis, HCMV
microRNAs miR UL112-1, US5-1, and US5-2 target mRNAs of several host proteins
involved in regulation of the cellular secretory apparatus (105). A recombinant virus that
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does not express these miRNAs did not induce formation of cVAC and produced
significantly fewer infectious virions. Ectopic expression of these microRNAs had some
effects on Golgi structures, but full cVAC did not form.
In prior studies we described the three dimensional structure of the cVAC, and
the extensive remodeling of the cytoplasm and shifts in organelle identity that occur
during cVAC development (98).

The objective of this work was to identify HCMV

protein-coding genes that regulate cVAC biogenesis. Using siRNAs that target a set of
26 candidates, we identified three HCMV genes (UL48, UL94, and UL103) whose
absence results in abrogation of cVAC development, without affecting expression of
other viral genes. Our results expand the set of functions assigned to HCMV genes,
and will enable identification of the network of interactions between HCMV and the host
cell secretory apparatus, provide new information about the process of virion assembly,
and define new targets for development of novel antivirals.
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Materials and Methods
Cells and virus. HCMV (AD169) (American Type Culture Collection, Manassas,
VA) was grown in low passage human foreskin fibroblasts (HFF) in complete
Dulbecco’s modified Eagle (DMEM) medium plus sodium pyruvate and MEM
nonessential amino acids (Invitrogen, Carlsbad, CA), GlutaMAX (Invitrogen), and 5%
FBS (HyClone, Logan, UT). Virus was titrated by plaque assay on low passage diploid
human foreskin fibroblasts.

For growth curves, supernatant virus was collected,

purified, and stored at -80°C. The siRNA experiments reported here were performed in
low-passage human lung fibroblasts (HLF) (a gift from John Stewart, Centers for
Disease Control and Prevention, Atlanta, GA) that were propagated in the medium
described above but with 10% FBS and penicillin and streptomycin. Antibiotics were
omitted during experiments.
siRNA screening and immunofluorescence assay. Cocktails of four siRNAs
that specifically target each candidate HCMV regulator of cVAC biogenesis were
designed and synthesized by Dharmacon Inc. (Lafayette, CO). For the transfection
experiments, 2 x 104 HLF cells per well were seeded onto 0.2% gelatin coated 8-well
glass chamber slides (LabTek, Nunc, Rochester, NY; catalog number 177402) for 1 h at
37°C. The following day, cells were transfected with 50 pmol SMARTPOOL siRNA
using Lipofectamine 2000; 6 h after transfection, cells were infected at a multiplicity of
infection (MOI) of 0.2 in DMEM containing 5% fetal bovine serum.

As previously

described (16), after 120 h, cells were washed with PBS, fixed with 4%
paraformaldehyde in PBS (lacking Ca2+ and Mg2+) at pH 7.4, and then autofluorescence
was quenched by incubation for 15 min in 50 mM ammonium chloride. Cells were
subsequently permeabilized and then successively incubated with the primary
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antibodies (described in Table 1) and fluorescent tagged secondary antibodies (Alexa
Fluor 488- conjugated goat anti-mouse IgG and Alexa Fluor 568-conjugated goat antirabbit IgG both from Molecular Probes, Carlsbad, CA).

Mounting was done with

Vectashield containing DAPI (4’, 6-diamidino-2-phenylindole) (Vector Laboratories Inc.,
CA). Imaging was done on a Leica TCS SP5 laser scanning confocal microscope.
Construction of recombinant viruses.

Recombinant HCMV viruses were

generated by recombineering using the AD169 bacterial artificial chromosome, pAD/Cre
in SW105 (gift from Donald L. Court, National Cancer Institute), an E. coli strain which
contain a temperature sensitive recombinase gene and an arabinose inducible Flp gene
(106, 107). pAD/Cre contains the AD169 genome flanked by loxP sites that excise the
bacterial component of the BAC upon transfection into mammalian cells.

Due to

overlapping adjacent coding regions at the 5’ end of the UL48 and UL103 genes, the
FKBP segment (108), was inserted at the 3’ end of the target genes. Selective markers
(galK and kanamycin) flanked by FKBP and FRT sequences were PCR amplified from
pYD-C630 (provided by Dong Yu, Washington University) (109).

Primers for

recombineering are listed in Table 2. Positive selection of the FKBP GalK/kanamycin
cassette was carried out on kanamycin Luria broth agar plates. Selection markers were
removed by inducing the SW105 Flp recombinase, leaving UL48-FKBP or UL103-FKBP
with an FRT site in frame at the C-terminus. Removal of the GalK selection marker was
verified by selection on galactose indicator plates. Galactose negative colonies were
picked, and verified by restriction enzyme analysis, PCR, and DNA sequencing. To
create UL103-FKBP-V5, the GalK/kanamycin cassette was replaced by amplifying and
recombining the V5 tag. Negative selection of the GalK was performed on M63 minimal
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media plates supplemented with glycerol, D-biotin, L-leucine, 2-deoxygalactose, and
chloramphenicol. Loss of the GalK was verified as described above. All viruses were
reconstituted by using Lipofectamine 2000 to transfect HFFs with 8-10 µg of BAC DNA,
followed by propagation in the presence of 1 µM Shield-1 (Cat no. CIP-AS1,
Cheminpharma, Farmington, CT), which was replaced every 48 hours to maintain its
activity. Virus was collected when the monolayer showed >80% cytopathic effect. Virus
stocks were grown by infecting HFFs at a multiplicity of infection of 0.01 in the presence
of 2 µM Shield-1; extracellular virions were partially purified by centrifugation through a
20% sucrose cushion.
Immunoblots. HFFs were grown to confluence in T25 flasks and mock infected
or infected at an MOI of 0.1. At 5 dpi, cells were washed with PBS and then lysed with
RIPA buffer (0.1 M Hepes pH 7.4, 0.1% sodium deoxycholate, 150 mM NaCl, 1% NP40, 0.1% SDS, and Roche protease inhibitor). Protein concentrations were determined
by BCA assay (Pierce, Rockford, IL). Equal amounts of protein solubilized in 2X SDS
Laemmli buffer with 2-mercaptoethanol were separated in 10% SDS polyacrylamide
gels, transferred to nitrocellulose membranes (Whatman, Florham Park, NJ), probed
with primary antibodies, and then reacted with HRP-conjugated goat anti-rabbit/mouse
IgG secondary antibodies (Thermo Scientific, Rockford, IL). Reactions were detected
with the Supersignal West Pico Chemiluminescent substrate (Thermo Scientific,
Rockford, IL) on autoradiography film (GE Healthcare, Pittsburgh, PA). Antibodies are
listed in Table 1.
Electron microscopy.

Transmission electron microscopy was done by Dr.

Hong Yi at the Robert P. Apkarian Integrated Electron Microscopy Core Facility of
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Emory University, Atlanta, GA, using methods developed Dr. Yi in collaboration with
Ahlqvist, Tandon, and Mocarski (58, 103). Briefly, HFF were infected in the presence
and absence of Shield-1 with the parental (pAD/Cre) or the UL103-FKBP virus at MOI =
0.3. At 120 hpi cells were washed with fixative (2.5% glutaraldehyde in 0.1 M sodium
phosphate buffer (pH 7.4)), and then incubated in fixative for 20 min at room
temperature. After overnight storage in fixative at 4°C, cells were shipped submerged in
the fixative.

Cells were postfixed in the same buffer with 1% osmium tetroxide,

dehydrated through a graded series of ethanol, and then embedded in an epoxy resin.
Cell culture dishes were broken, and ultrathin sections were then cut and
counterstained with uranyl acetate and lead citrate. The Hitachi H-7500 was operated
at 75 kV, and images were captured using a Gatan BioScan (Pleasanton, CA) chargecoupled device camera.
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Results
Screening strategy to identify viral genes required for cVAC development.
Based on the requirement for viral DNA synthesis for cVAC biogenesis, and the
hypothesized importance of the cVAC in virion maturation, we identified 26 HCMV
genes as possible regulators of cVAC biogenesis (Table 3) and used siRNAs to
individually silence them during infection.

Effects on cVAC development were

visualized by confocal microscopic analysis of markers that are collectively diagnostic
for cVAC structure.
The synthetic siRNAs used were mixtures of 4 siRNA duplexes, each of which
independently targets the transcript of interest (Dharmacon SMARTpools). Use of such
pools instead of single siRNAs increases specificity by reducing the input concentration
of individual siRNAs, thereby reducing off target effects.

Pools also increase the

likelihood of successful silencing because four regions of the target gene are targeted at
once.

Although antibodies are not available against most of the proteins whose

expression we targeted, similarly designed siRNA pools that target HCMV proteins for
which we have antibodies (IE2, MDBP, UL99, US17, and US18) delivered satisfactory
results for every target tested ((110) and data not shown).

Nonetheless, negative

effects of individual siRNA pools should not be taken as proof that the targeted gene
has no effect on cVAC biogenesis.
Screening experiments were done in 8-well glass chamber slides. Human lung
fibroblast (HLF) cells were transfected with the siRNAs 6 to 8 hr prior to infection with
fully infectious HCMV (AD169).

As a reminder, siRNAs do not affect input protein
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levels, but reduce levels of proteins expressed from genes transcribed during infection.
At 120 hpi, cells were fixed and stained with the indicated antibodies.
The antibodies used in our antibody cocktails give reliable and distinct staining
patterns that are collectively diagnostic for cells being infected, expression of viral late
genes, and formation of the cVAC (Fig. 4A; Table 4).

To validate the screening

strategy, we used 100 µg/ml phosphonoacetic acid (PAA)-treated, HCMV-infected cells
as a prototype of a gene silencing experiment. PAA inhibits viral DNA synthesis,
consequently inhibiting cVAC biogenesis in HCMV infected cells. As shown in Fig. 4B,
in the presence of PAA, markers of the secretory apparatus in infected cells resembles
those in uninfected cells.
HCMV genes involved in cVAC biogenesis identified through the use of
siRNAs. Over 400 confocal images were analyzed as part of the screening process.
Phenotypes observed after siRNA treatment included: no effect, toxic effects, absence
of HCMV late gene expression, and inhibition of cVAC formation in cells where HCMV
late genes are expressed.

Candidate regulators of cVAC biogenesis were defined as

genes whose silencing did not affect HCMV gene expression but prevented formation of
perinuclear Golgi rings surrounding concentrations of EEA1 staining, with emphasis on
the EEA1 patterns.
The results from our siRNA screen of 26 HCMV genes are summarized in Table
5. Some siRNAs had no visible effects on infected cells, while others caused extensive
cytopathic effects, including blobs of dead cells, small nuclei, and irregularly shaped
nuclei.

These diverse effects might be products of silencing viral genes that are
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involved in regulating any of a variety of cellular processes, including protein secretory
pathways, cellular metabolism, and anti-apoptotic activity.
The three genes whose siRNAs resulted in the most significant and specific
effects on cVAC development were UL48, UL94, and UL103.

In the presence of

siRNAs against each of these genes, HCMV late genes were expressed, Golgi rings
formed in few cells, and the early/recycling endosome machinery was dispersed, nearly
absent, or otherwise disrupted (Fig. 5).

An important pathognomonic change

associated with HCMV infected cells is development of enlarged nuclei that take on a
reniform (kidney bean) shape; these changes are important during cVAC biogenesis
(93). Knockdown of all three of the candidate cVAC biogenesis regulators (UL48,
UL94, and UL103) resulted in significantly lower ratios of reniform to oval nuclei
compared to untreated cells and cells treated with siRNAs against several other genes
targeted in our screening (Fig. 6). Some of the known properties of these candidate
regulators are listed in Table 6.
Use of regulated protein destabilization to verify the siRNA screening
results. To independently confirm the siRNA results, and to address specificity issues
that might arise from overlapping transcripts previously described across UL48, UL94
and UL103, we employed regulated FKBP-mediated protein destabilization of the
proteins of interest (Fig. 7; (108)). The FKBP moiety targets tagged proteins for rapid
proteasomal degradation, and the stability of the proteins tagged with FKBP domains
can be regulated by the concentration of Shield-1.

Due to coding region overlaps

between each of the genes of interest and their upstream neighbor, the FKBP domain
was fused in place of the stop codon at the C-terminus of each protein. Recombinant
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BACs were transfected into two cultures that were grown in the presence and absence
of Shield-1. The UL48 recombinant (UL48-FKBP) produced many fewer and much
smaller plaques in the absence of Shield-1 (data not shown), providing a preliminary
indication that the FKBP domain was having the desired effect. As expected because
UL103 deletion mutants are viable, the UL103 recombinants (UL103-FKBP and UL103FKBP-V5) produced infectious virions under both conditions. We were not able to
reconstitute a viable virus from a UL94-FKBP BAC.
We used immunofluorescence and immunoblots to verify our ability to regulate
the stability of the proteins of interest. pUL48 was detected using an antibody against
its N-terminus (kindly provided by Wade Gibson) (111).

Because highly specific

antibodies are not available for detection of pUL103, a 14 amino acid V5 epitope tag
was added to the C-terminus of UL103-FKBP (UL103-FKBP-V5).

For UL48-FKBP,

addition of Shield-1 markedly increased the amount of pUL48 detected by
immunofluorescence (Fig. 8A) (6.2-fold per cell based on 3D quantification of at least 8
cells for each condition). By densitometry, there was a 3.1-fold increase of pUL48 in the
presence of Shield-1 (Fig. 8C). The amount of pUL48 expressed by the UL48-FKBP
virus in the presence of Shield-1 is less than that produced by the parental virus. When
UL103-FKBP-V5 is grown in the absence of Shield-1, the UL103-FKBP-V5 protein is
very faint and dispersed when visualized by immunofluorescence, with marked
increases when Shield-1 is present (3.1-fold by IFA and 4.2-fold in immunoblots) (Fig.
8B and 8D). Thus, addition of the FKBP destabilization domain to pUL48 and pUL103
enables regulation of their stability. Immunoblots showed little difference in expression
of virus genes from all three lytic classes in the presence or absence of pUL48 or
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pUL103 stabilization (Fig. 9), and only modest differences were seen in intracellular
DNA levels by quantitative PCR (data not shown).
Having verified the intended effects of Shield-1 on viral proteins, the effect of
regulated protein degradation on cVAC structure was analyzed by staining viral and
cellular markers of the cVAC in the presence or absence of Shield-1 (Figs. 10 and 11).
Shield-1 had no significant effect on cVAC development for the parental virus (Fig. 11).
pUL48 destabilization in absence of Shield-1 led to dispersal of early/recycling
endosomes, and absence of the characteristic Golgi ring, as was seen in the siRNA
experiments. cVAC biogenesis appeared to be normal in most cells in which pUL48
was stabilized with Shield-1. Similar results were seen for UL103-FKBP. In an anaylsis
of over 800 cells, cVAC disruption in the absence of Shield-1 was statistically significant
(p<0.0001) (Fig. 11). Thus, in accordance with the siRNA screen, destabilization of
pUL48 and pUL103 disrupted cVAC formation, verifying their importance in cVAC
biogenesis.
Growth properties of recombinant viruses in the presence and absence of
Shield-1. The siRNA and protein stability experiments described above were done at
low multiplicity and employed cVAC morphology endpoints visible in infected cells at 4
or 5 dpi. To determine whether destabilization of pUL48 or pUL103 influences virus
growth, we compared the growth of three recombinant viruses (UL48-FKBP, UL103FKBP, and UL103-FKBP-V5) with their parent (pAD/Cre). Time courses of production
of extracellular infectious virions were examined at low and high MOI (multi- and singlestep growth curves, respectively). At low MOI, not all cells are infected at the time of
inoculation. Thus, multiple rounds of replication can take place, enabling examination of
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virus dissemination in terms of production of secondary plaques, features such as
plaque size, and dependence on conditions created when cells are not exposed to large
numbers of viral particles, many of which are not independently infectious (e.g., HCMV
dense bodies and non-infectious enveloped particles). At high MOI, essentially every
cell in the culture is infected simultaneously, and cells are also exposed to large
numbers of bioactive non-infectious particles. Such synchronized infections provide
information about how much infectious virus is produced during a single round of
replication.
For UL48-FKBP, the single- and multi-step growth infections were done in the
presence or absence of Shield-1 (Fig. 12A). Progeny extracellular virions were titered
in triplicate in the presence of the drug.

Somewhat unexpectedly, the single-step

growth curves for UL48-FKBP showed one-log growth defects starting at 3 dpi,
regardless of whether Shield-1 was present or absent; the defect persisted over the 6
day experiment. Likewise, in the multi-step analysis, UL48-FKBP growth was similar in
the presence and absence of Shield-1; mutant infectious progeny were first detected at
6 dpi, and infectious yields lagged by ~3 logs until 15 dpi, when they were about 1 log
lower than for the parental virus. Inefficient growth of the UL48-FKBP virus might be
attributable in part to the lower overall level of pUL48 expressed in the presence or
absence of Shield-1 (Fig. 8C).
The UL103-recombinant virus stocks were also grown with Shield-1. In singleand multi-step analyses, the presence of Shield-1 had little effect on the yield of
extracellular infectious virus (Fig. 12B). Titers were similar when measured in the
presence or absence of Shield-1 (data not shown), the only difference being plaque
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sizes (see below). In the single-step experiment in the absence of Shield-1, the UL103FKBP recombinant virus produced infectious extracellular virus at rates similar to its
parent at most time points, with a <10- fold difference at 3 dpi. In contrast, Ahlqvist and
Mocarski found up to a 50-fold decrease in extracellular infectious titer with a TowneBAC mutant that does not express pUL103 (15). These results suggest that at high
multiplicities of infection, there is some compensation for the absence of pUL103 by a
complementary function likely provided by another viral protein.

In multi-step

experiments, the UL103-FKBP and UL103-FKBP-V5 viruses lagged in extracellular
virus production by 2 to 3 logs at 3 and 6 dpi, ultimately reaching parental titers 9 to 15
dpi. In marked contrast, a pUL103-null virus produced ~3000-fold less extracellular
infectious titer (15). This indicates that even small amounts of pUL103 expressed by
the UL103-FKBP virus are sufficient to support near parental growth. The latter point is
supported by our observations that (i) at low multiplicities, the small amount of pUL103
produced by our FKBP-tagged viruses is sufficient to rescue about two logs of the early
(3 to 6 dpi) growth defect seen in the absence of pUL103, with the growth defect being
overcome 9 to 15 dpi, and (ii) growth of these viruses at moi = 0.1 was similar to that in
the single-step analysis (data not shown); the growth defect was only seen at low moi.
In other growth experiments with FKBP-tagged UL48 and UL103 viruses, we saw
little effect of Shield-1 over concentrations ranging from 0 to 4 μM/ml (data not shown).
These results suggest that although the FKBP domain enables regulated stability of
pUL48 and pUL103, as well as regulation of their activity in cVAC biogenesis, for both
proteins the FKBP tag inhibits some aspect of production or egress of infectious virions.
As mentioned, for pUL103, this effect was largely overcome by 9 to 15 dpi.
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Ahlqvist and Mocarski found that viruses deficient in expression of pUL103
produce significantly smaller plaques (58). Consistent with this, we found that Shield-1
could rescue the small plaque phenotype of the UL103-FKBP virus (Fig. 13). Thus, in
addition to its roles in cVAC biogenesis and virion maturation or egress, pUL103 has a
role in cell-to-cell spread of infection. In contrast, the UL48 recombinant virus produced
small plaques in the presence and absence of Shield-1 (data not shown).
In ultrastructural analyses, in the absence of Shield-1, cytoplasmic UL103-FKBP
virions were more likely to have aberrant appearances, including frequent appearance
of virions that appeared to be arrested or greatly slowed down in the midst of acquiring
their envelope (Fig. 14).
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Discussion
Little is known of the effectors of HCMV cVAC biogenesis, a biological process
that is distinct from cVAC operation.

Structures architecturally similar to the cVAC

(Golgi rings surrounding a cluster of early/recycling endosomes, and spatial segregation
of the early/recycling and late endosomal systems) have been identified in uninfected
cells (112-114). cVAC biogenesis may thus be a product of the virus activating, and
possibly modifying, a previously programmed biological process. Like other biological
pathways regulated by HCMV (e.g., immune responses, apoptosis, and the
AKT/PI3K/mTOR pathway) (115, 116), we anticipate multiple points of control of the
process by the virus, including the recently described role of HCMV microRNAs in cVAC
biogenesis (105). In addition to the virologic lessons, elucidation of this pathway and its
points of control will be informative with respect to important areas of cell biology.
Using siRNAs, we screened HCMV early/late and late genes known to be
important for efficient lytic replication for their activity in cVAC biogenesis. Of the 26
genes tested, only inhibition of expression of UL48, UL94, and UL103 specifically
prevented cVAC biogenesis: Golgi rings did not form and the early/recycling endosome
complex was disrupted, in the context of infections that had proceeded to at least late
gene expression.
The genes for all three candidate cVAC regulators have coding regions that
overlap with coding regions of their neighboring genes, and polycistronic transcripts
span each gene locus (Fig. 7). To address the possibility that the siRNA effects were
due to silencing of overlapping transcripts, we tagged each candidate protein with a
regulatable post-translational destabilization domain.

Although we were not able to

reconstitute a viable virus from a BAC containing a tagged version of UL94, viable
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recombinants were reconstituted for UL48 and UL103, and we demonstrated regulated
stability of the proteins of interest. HCMV IE, early, and late genes were expressed at
near-parental levels regardless of pUL48 or pUL103 degradation.

When pUL48 or

pUL103 were destabilized, cVAC biogenesis was impaired, in a manner similar to what
was seen following siRNA treatment, thus confirming the siRNA result and verifying its
specificity for these genes.
Our siRNA results are consistent with prior reports that HCMV UL94 and UL103
are important for late stages of HCMV virion assembly and egress (55, 58). From the
UL103-FKBP virus we learned that the pUL103 domain necessary for cVAC biogenesis
is distinct from at least two other functional domains. Specifically, defects in plaque size
(Fig. 13) and secondary envelopment (Fig. 14) were able to be rescued by Shield-1,
and the C-terminal FKBP tag appears to alter production of extracellular infectious virus
in a manner that is impervious to, and possibly worsened by stabilization of the tagged
protein with Shield-1 (Fig. 12B). We also provide new evidence that HCMV pUL48 is
important for production of infectious extracellular virus, perhaps analogous to the role
of its herpes simplex virus 1 homolog in production of non-infectious light bodies (117).
Similar to the behavior of the UL103-FKBP virus, this defect in the UL48-FKBP virus
was not rescued by Shield-1, in contrast to the cVAC biogenesis activity. More detailed
studies of the roles of these proteins in cVAC biogenesis will require generation of
reagents that do not include tags that interfere with functions of the proteins of interest.
The three HCMV proteins whose silencing prevented cVAC formation are virion
tegument proteins that are conserved across the Herpesviridae (Table 6). It has been
suggested that HCMV UL103 and its orthologs in other herpesviruses play related roles
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in the final stages of virion assembly (58). While structures analogous to the HCMV
cVAC have not been identified for other herpesviruses, is possible that these conserved
proteins are all involved in remodeling infected cells into virus production factories.
It is clear that multiple viral and cellular gene products play important roles in
cVAC biogenesis. We hypothesize that collective interactions of these factors, with
each other and with other viral and cellular proteins, establish an environment
conducive to cVAC development. The viral proteins identified here as regulators of
cVAC biogenesis will be useful probes for identifying and understanding the network of
viral and cellular genes involved in cVAC biogenesis and virion maturation, a necessary
prelude to developing novel antivirals that block the process.
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TABLE 1. Antibodies used in IFA and immunoblot assays
Antibody target

Host/isotype, clone

Source, catalog no.

Epitope tag
V5 (14 amino acids)

Mouse monoclonal/IgG2aκ

LifeTechnologies, R960-25

Cellular
GAPDH (36 kDa)

Mouse monoclonal/IgG1, clone GA1R

ThermoScientific, MA5-15738

GM130 (130 kDa)

Mouse monoclonal/IgG1(κ),clone 35/GM130

BD Biosciences, 610822

EEA1 (180 kDa)

Rabbit polyclonal

Abcam, ab2900

Mouse monoclonal/ IgG1(k), clone CH160

Virusys, P1215

Mouse monoclonal, clone 8B1.2

Chemicon (Millipore), MAB810

pUL44 (CMV ICP36), 46 kDa

Mouse monoclonal/ IgG1(k), clone 10D8

Virusys, CA006-100

UL48 (N-terminal region)

Rabbit polyclonal

pUL99 (pp28)

Mouse monoclonal/IgG2A(k), 5C3

Wade Gibson (Johns Hopkins
University) (118)
Virusys, CA004-100

gB (55 kDa and 110 kDa)

Mouse monoclonal/ IgG1(k), clone 2F12

Virusys, CA005-100

HCMV
IE1 and IE2 (IE1, 72kDa; IE2,
86kDa)
IE2 (86kDa)

5' -CACATGCCACTCTCGTCTTCGATGTGGAGCTTCTAAAACCGGAAGAATTCggtaagcctatccctaaccc- 3'

5' -GTTGCGTGTTTTTTTTTTTTCTATGATATGCGTGTCTAGTTCGCTTCTCAcgtagaatcgagaccgagga- 3'

5'-TGCCCTCACCCCCCAAGCTGCCGCCGCGCTGGGAACGAGGAGAGGAAGAGatgggagtgcaggtggaaaccatc-3’

5'-GTTGCGTGTTTTTTTTTTTTCTATGATATGCGTGTCTAGTTCGCTTCTCAgctggagctccaccgcgggaagttc-3'

V5 tag

FKBP-GalK/Kan tag

*The uppercase sequences correspond to the 50-bp segments of viral DNA needed for recombination into the viral genome. The lowercase sequences are
regions needed to enable amplification of exogenous sequences (e.g., the V5 epitope) intended to be inserted into the BAC

UL103-FKBP-V5

UL103-FKBP

FKBP-GalK/Kan tag

UL48-FKBP

5'-ACGATAAAAATCCTATTGTTTTTATTACCCGCTACTGTCAGTGTCGGTTAgctggagctccaccgcgggaagttc-3'

Amplification target

Primer sequence*

5'-CGCAATCCGTACAGGACACTATTCAACACATGCGGTTTCTCTATCTTTTGatgggagtgcaggtggaaaccatc-3'

Virus

TABLE 2. Primers used for generating recombinant viruses
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TABLE 3. Targets for siRNA screening: HCMV Early-Late and Late genes essential or
important for viral growth
Function

Gene(s)

Tegument

R: UL97*
E: UL32, UL48, UL82, UL94, UL99

Glycoproteins

E: UL55, UL73, UL75, UL100, UL115

Unknown

R: UL21, UL29, UL30, UL69, UL103, UL117
E: UL34, UL49, UL71*, UL76*, UL91, UL92, UL93, UL95, UL96

R = reduced; viral growth reduced by at least 50-fold
E = essential; no viral replication its absence
Replication data are from (84) and (85), kinetic class assignments are from (83).
*Kinetic class not assigned in (83).
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TABLE 4. Targets and purposes of antibody cocktails used in screening assays
Antibodiesa
Mouse Monoclonals
Cocktail

IE2

A

+

pUL99

EEA1

+

C

+

D

F
G
H
a+,

GM130

+

B

E

Rabbit Polyclonals

+
+
+
+

MannII

US18

Purposeb

+

confirms infection and Golgi ring formation

+

confirms Golgi ring formation, and late
gene expression and localization

+

confirms Golgi ring formation and EEA1
relocalization

+

confirms Golgi ring formation

+

confirms infection, and late gene
expression and localization

+

confirms late gene expression

+

confirms EEA1 relocalization, and late
gene expression and localization

+

confirms Golgi ring formation, and late
gene expression and localization

present in cocktail
IE2, pUL99 and US18 detect different stages of infection, GM130 and Mann II stain Golgi rings, and
EEA1 localizes at the center of cVAC.
b
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TABLE 5. HCMV genes screened by siRNA: properties and silencing results
Candid
ate
cVAC
Unusual cytopathic
Effect on Golgi and EEA1 regulat
Gene propertiesa
orc
effectsb
Late gene expression
markers
Enhances replication
Yes
No change in expression Small effect on Golgi
of pUS18/gB
markers, but not on EEA1
None
Unknown
Yes (Many nuclei are No change in the
very small, blob of
expression of pUS18
dead cells and empty and pUL99
patches)
Unknown; alters PML morphology Yes (Blob of dead cells No change in expression Small effect on Golgi
and empty patches)
of pUS18/gB
markers, but not on EEA1
siRNA results

Gene
UL21A
UL29

UL30
UL32

Major tegument protein, binds to
capsid

Yes (Blob of dead cells Reduced (Altered
and altered nuclear
distribution of pUL99
form)
[mainly cytoplasmic])

UL34

Represses US3 transcription;
shuttles between nucleus and
cytoplasm

Yes

UL48

Large tegument protein; ubiquitin- Yes
specific protease (N-terminal
region); involved in capsid
transport

UL49

Unknown

Yes (Many small
nuclei)

UL55
(gB)

Virion envelope glycoprotein, gB;
involved in heparan sulfate
mediated virion entry, and cell-tocell spread
Tegument protein; multifunctional
regulator; shuttles between
nucleus and cytoplasm; inhibits
pre-mRNA splicing; exports virus
mRNA from nucleus
Tegument protein; involved in
virion morphogenesis

Yes

UL69

UL71

Virion envelope glycoprotein, gN,
complexed with envelope gM;
supports virion morphogenesis

Yes (Many small
nuclei)

UL75
(gH)

Virion envelope protein, gH;
complexed with envelope gL;
involved in cell entry, and cell-tocell spread

Yes (Many small
nuclei)

UL76

Virion protein; affects translation
of UL77
Tegument phosphoprotein pp71;
upper matrix protein; involved in
gene regulation
Unknown

Yes

UL82

UL91
UL92

Altered distributions of
pUL18 and pUL99

Golgi markers did not form
good rings, but EEA1 was
still in tight perinuclear
cluster.
Higher proportion of
Fuzzy and diffuse EEA1;
altered localization of
pUS18 in non-cVAC
cytoplasm; expression
Golgi markers, and
of pUL99 reduced
absence of Golgi rings;
few conventional cVACs
No change in expression Small effect on Golgi
of pUS18, but gB was
markers, but not on EEA1
more diffuse
Altered distribution of
Small effect on Golgi
pUS18, and reduced gB markers, but none on
expression
EEA1

Yes (Empty patches, Higher expression of
irregular forms of
pUS18 in non-cVAC
nucleus and
cytoplasm;altered
sometimes stretched) expression pattern of
pUL99
Yes (Blobs of dead
Reduced; Altered
cells)
distribution of pUL99

UL73
(gN)

Yes (Many small
nuclei)
Yes (Many small
nuclei)

Unknown; members of this family Yes (Many nuclei are
found in several herpesviruses,
very small, blob of
including EBV BDLF4, HCMV
dead cells and
UL92, HHV8 ORF31 and HSV6
empty patches)
U63

None

Expression of pUS18
reduced;altered
distribution pattern of
pUL99
Expression of pUS18
reduced;altered
distribution pattern of
pUL99, mostly
cytoplasmic
Small altered expression
of pUS18 and pUL99
No change in expression
of US18, but reduced
gB expression
No change in expression
of pUS18 and pUL99

None

None
None

Reduced expression of
Golgi markers and EEA1
but no changes in their
arrangement
Altered distribution of Golgi
markers but not EEA1
Altered and reduced
expression of Golgi
markers, but not on EEA1
Altered distribution of Golgi
markers but not EEA1

Slightly altered expression None
of US18 and pUL99

Yes
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UL93

UL94

UL95

UL96

UL97

Capsid-associated; involved in
DNA encapsidation and capsid
transport
Tegument protein; involved in
virion secondary envelopment

Yes (Blob of dead cells Slight altered expression None
and empty patches)
of pUS18, but not in
pUL99
Yes
No effect on pUL99 or
Greatly reduced EEA1
pUS18 expression
expression; partial effect
levels.
on Golgi markers, forming
small Golgi ring
Yes (Blob of dead cells Slightly altered expression Altered distribution of Golgi
and empty patches)
of pUS18, but not
markers but not EEA1
pUL99

Late gene activator; found in
several herpesviruses, include
EBV BGLF3 and other UL95
proteins (e.g., HCMV UL95, HSV1 UL34, and HHV6 U67)
Tegument protein; stabilization of Yes (Many blob of
nucleocapsids during nucleodead cells)
cytoplasmic translocation;
possibly involved in virion
morphogenesis
Tegument protein; virion
Yes
serine/threonine protein kinase

Altered distribution;
None
increased expression of
pUL99

Reduced

None

Reduced

None

UL99

Myristylated tegument protein;
involved in virion morphogenesis

UL100
(gM)

Virion envelope glycoprotein, gM; Yes (Blob of dead cells Slightly altered distribution Altered expression of Golgi
8 transmembrane domains;
withnuclear debris,
of pUS18 and pUL99
markers, but not of EEA1
complexed with envelope gN;
patches of empty
involved in virion morphogenesis
spaces and many
small nuclei)
Tegument protein; involved in
Yes (Big empty
US18 looks normal, but Golgi markers and EEA1
virion and dense body egress;
patches)
altered distribution of
are greatly reduced;
DNA encapsidation
UL99
Altered distribution of
Golgi markers
Virion glycoprotein gL; complexed Yes (Blobs of dead
Less abundant (late virion Reduced EEA1 expression;
with envelope gH; involved in cell
cells)
proteins/cVAC markers) little effect on Golgi
entry andcell-to-cell spread
markers; Golgi rings with
EEA1 center still present
Enhances replication
Yes (Many are very
Expression of pUS18
Little effect on Golgi
compartment formation; impairs
small and bright blue altered fuzzier cVAC
markers or EEA1
cellular DNA synthesis
blobs [apoptotic
association; altered
distribution pattern of
debris?])
pUL99 in some cell

UL103

UL115

UL117

a Gene

Yes

Yes

Yes

function information is reviewed in (119).
In most instances, unusual cytopathic effects consisted of numerous blobs of dead cells and altered
nuclear forms (smaller, elongated, or irregular shapes).
c Candidate cVAC regulators are the genes we selected for further study; this does not preclude other
genes being important in the process.
b
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TABLE 6. Properties of candidate regulators of HCMV cVAC biogenesisa
HCMV
gene

HSV

γHV

HHV6

Functions and properties of HCMV homolog

Interacting viral
partners
(HCMV only)

UL48

UL36

ORF64

U31

Essential
Largest tegument protein
Has deubiquitinating enzyme activity
Role in intracellular capsid transport

pUL45, pUL47,
pUL50, pUL69,
pUL88, pUL103,
and pUL132

UL94

UL16

ORF33

U65

Essential
Tegument protein
Binds single-stranded DNA
Cytoplasmic egress

pUS22, pUL72,
pUL82, and pUL99

UL103

UL7

ORF42

U75

Elimination of pUL103 expression reduces virus replication
by 102 to >104-fold, and results in reduced plaque size.
May have a role in viral replication
Tegument protein
Associated with the cVAC
Virus particle and dense body egress

pUL22A, pUL48N,
and pUL103

Homologs

aInformation

in this table is from the following references: (55, 58, 67, 84, 85, 120-123)
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Figure 4. Validation of siRNA screening system. (A) Diagrammatic representation of
cVAC staining pattern in the HCMV infected human lung fibroblasts, and the predicted
outcomes following silencing of cVAC biogenesis regulators. The illustrated patterns
are representations of previously published data (47, 96, 98). (B) Inhibition of cVAC
biogenesis by PAA (Cat. no. P6909, Sigma-Aldrich, St. Louis, MO) treatment in HCMV
infected fibroblasts; confocal images are shown alongside the predicted patterns.
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Figure 5. siRNA-based identification of UL48, UL94, and UL103 as candidate
regulators of cVAC biogenesis. Cells were treated with siRNA pools designed to
target the indicated HCMV genes, stained with antibodies against the indicated cellular
markers and then examined by confocal microscopy. A subset of the results obtained
using the full panel of markers illustrated in FIG. 3 is shown here. The staining patterns
for the full set of markers were consistent with UL48, UL94, and UL103 playing
important roles in cVAC biogenesis.
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Figure 6. Ratios of reniform and oval nuclei in HCMV infected cells after gene
silencing. HCMV infected cells with reniform or oval shaped nuclei were counted in
cells with or without silencing of the indicated genes. The significance of the differences
were evaluated using the Chi Square test. n, number of cells examined for each
condition; p, level of significance.
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Figure 7. Gene arrangements and transcripts in the vicinity of the candidate
regulators of cVAC biogenesis. 5’ ends of mRNAs are indicated with balls, and 3’
polyadenylated regions with “An”. Genetic recombineering methods described in
Materials and Methods were used to introduce the FKBP degradation domain into our
genes of interest. All three genes overlap with neighboring genes at their 5' end. To
avoid effects on overlapping coding regions at the N-termini of the three genes, the
FKBP destabilization domain was added at the C-terminus of each gene. UL48 maps:
(124); UL94 maps: (125-127); PRV UL7 (HCMV UL103 homolog) map: (124) and
HCMV UL103 (22).
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Figure 8. Verification of regulated protein degradation. The UL48-FKBP and UL103FKBP-V5 tagged proteins were analyzed by (A and B) confocal immunofluorescence
microscopy, and (C and D) immunoblots in the presence and absence of Shield-1.
HFFs were infected for 120h at a MOI of 0.1. pUL48 was detected using an antibody
against its N-terminus (C), and pUL103 was detected using an anti-V5 antibody (D).
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Figure 9. Effect of protein destabilization on other HCMV proteins. Cells were
infected (MOI = 0.1) with UL48-FKBP and UL103-FKBP in the presence and absence of
Shield-1 and then analyzed by immunoblots at 24 and 120 hpi, using antibodies against
representative immediate early (IE1 and IE2), early (UL44), and late (pp28/UL99) viral
proteins. GAPDH was used as a loading control.
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Figure 10. Effects of regulated protein degradation on cVAC biogenesis. Cells
were infected with the indicated viruses in the presence or absence of Shield-1 for 120
hr and then stained for cellular markers of the cVAC (cytoplasmic staining) and infection
(IE2, nuclear staining). Shield-1 had no effect on assembly complex development for
the parental virus, whereas destabilization of pUL48 and pUL103 led to dispersal of
early/recycling endosomes, and absence of the characteristic Golgi ring.
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Figure 11. Relative abundance of regular vs irregular cVAC structures in the
presence and absence of Shield-1. Regular structures displayed circular Golgi rings
and a concentration of EEA1-positive vesicles inside the rings. Irregular structures had
fragmented or abnormal Golgi shapes, and/or dispersal of EEA1-positive vesicles.
Statistical significance was measured using the Chi Square test (***, p<0.0001). n,
number of cells counted.
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Figure 12. Growth properties of recombinant extracellular viruses in the presence
and absence of Shield-1. (A) Replication of UL48-FKBP. (B) Replication of UL103FKBP and UL103-FKBP-V5. Virus replication at high (MOI = 3) and low (MOI = 0.01)
MOI (single step and multi-step growth curves, respectively) in presence or absence of
Shield-1. +, cells infected in the presence of Shield-1; -, cells infected in the absence of
Shield-1. Virus titers were determined in triplicate; the standard errors are too small to
be seen in the graphs.
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Figure 13. Plaque sizes of UL103 recombinant viruses in the presence and
absence of Shield-1 at 10 dpi. Plaque size (area) = mm2 +/- SEM, as measured from
photographs by using ImageJ (NIH) (128). In the absence of Shield-1, UL103-FKBP
plaque sizes were significantly smaller than for the other three conditions (t test, p < 105).
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Figure 14. Comparison of regular vs. irregular virions inside infected cells in the
presence or absence of Shield-1. Regular virions contain DNA and an envelope.
Irregular virions are in the process of envelopment or display an abnormal structure.
Statistical significance was measured using the Chi Square test (*, p < 0.1; ***, p <
0.0015). n, indicates the amount of viral particles counted.
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CHAPTER THREE
VIRAL AND CELLULAR INTERACTION PARTNERS OF pUL103
Introduction
Human cytomegalovirus (HCMV) induces a wide range of profound modifications
of host cell biology, including changes in cell morphology, cell cycle, metabolism,
intrinsic and innate immunity, and the endosecretory machinery.

Alterations in the

endosecretory machinery include remodeling of the Golgi and early endosomal
compartments to form the cytoplasmic virion assembly compartment (cVAC), where the
mature tegument is acquired, secondary envelopment occurs, and vesicles containing
mature virions are transported to the plasma membrane for release.
cVAC biogenesis is contingent on the expression of specific HCMV miRNAs and
late genes (105). Previously, we identified pUL48, pUL94, and pUL103 as being
important for cVAC biogenesis (129). When pUL103 is degraded during infection, the
cVAC does not form properly. pUL103 is a tegument protein that is conserved across
the Herpesviridae (HSV UL7 homolog)(Table 1). pUL103 and its homologs are
important for efficient production of infectious virions at low and high MOI. Ahlqvist and
Mocarski, as well as our lab, have identified roles of pUL103 in cell-to-cell spread, virion
envelopment and egress (58, 129). The mechanisms employed by HCMV pUL103 and
its relatives remain elusive.
Identification of protein-protein interactions can provide insights into the activities
of pUL103 during infection. Four HCMV proteins (pUL22, pUL48, pUL71, and pUL103)
were previously identified as pUL103 binding partners. In a yeast two-hybrid analysis
interactions were detected between pUL103 and itself, pUL22A, and pUL48N (120). An
interaction between pUL103 and pUL71 was identified by co-IP and bimolecular
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fluorescence complementation in uninfected cells (70). However, none of these
interactions were confirmed in the context of HCMV infection. During HSV-1 infection,
proper localization and incorporation into the virion of pUL7 (the HSV pUL103 homolog)
is dependent on its interaction with pUL51 (homolog of HCMV pUL71) (88). In addition,
HSV-1 pUL7 binds to the mitochondrial protein adenine nucleotide translocator (ANT2),
an interaction of uncertain significance (82). Viral and cellular binding partners of
pUL103 have not been studied in HCMV infected cells, leaving a void in understanding
the biological roles and mechanisms of pUL103.
To address this gap, we employed a set of complementary proteomics
approaches that employed co-IP and proximity biotinylation (BioID) to identify viral and
cellular proteins that interact with pUL103. Co-IP and the BioID system are well-suited
for detection of interactions that are strong and direct. The BioID system also enables
detection of weak, indirect, and transient interactions. The differences in these
complementary methods provide internal controls that reduce the number of false
positives, and interactions highly enriched in both approaches are more likely to be
specific. Using these methods, we identified multiple novel interactions with viral and
cellular proteins. pUL103 interacted with several cellular antiviral proteins, including
IFI16, and interacts with DNA-associated proteins and is present in nuclei. We also
found that pUL103 binds to ALIX (a component of the ESCRT machinery) via a novel
ALIX-binding site, a role for pUL103 in the redistribution of ALIX to the cVAC, and that
deletion of the ALIX binding site had a dominant negative effect on HCMV replication.
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Materials and methods
Cell culture and virus stocks.

Human foreskin fibroblasts (HFFs) below

passage 20 were grown in Dulbecco modified Eagle medium (HyClone-Thermo Fisher
Scientific, Waltham, MA) supplemented with 10% fetal bovine serum, 2 mM GlutaMAX
(Life Technologies, Grand Island, NY), and 1% minimal nonessential amino acids
(HyClone-Thermo Fisher Scientific, Rockford, IL). Virus stocks were propagated by
infecting 80% confluent HFFs at an MOI of 0.01 and collecting supernatant every 4
days. Virions present in cell culture supernatants were purified by centrifugation at 2700
rpm for 15 min to remove cell debris, and then ultracentrifugation (70,000 x g for 1 h)
through a 20% sorbitol cushion. Pelleted virions were resuspended and stored at -80ºC
in DMEM containing 10% FBS. Titers of virus stocks were determined by plaque assay
on confluent monolayers.
Plasmids. All cloning was performed in Escherichia coli DH5α. To construct the
BioID-UL103 plasmid (p), full length UL103 was amplified from pAD/Cre (primers listed
in Table 2) and inserted into the pcDNA3.1 mycBioID (Addgene, Cambridge, MA
plasmid #35700) (130) using XhoI and Aflll. UL103-V5-His(v) described in the following
section was used to generate UL103-V5-His(p) by inserting the V5-His-tagged UL103
gene into pcDNA3.1 between the KpnI and XbaI sites. Alanine substitutions and
deletion mutants were created by overlap extension PCR, followed by incorporation into
UL103-V5-His(p). All constructs were verified by DNA sequencing.
Recombinant viruses (BioID and V5-His).

Viruses were constructed by

recombineering using the HCMV AD169 bacterial artificial chromosome pAD/Cre (kindly
provided by Dong Yu) in SW105 cells (provided by the Court lab at the National Cancer

57

Institute). The UL103-V5-His and UL103-BioID mutants were created by inserting a
gene cassette at the extreme c-terminus of UL103. The GalK/Kan cassette was PCR
amplified from pYD-C630 (provided by Dong Yu) using 70-bp primers, 20-bp of which
corresponded to flanking sequences in pYD-C630 and the remaining 50-bp were
homologous to sites upstream and downstream of the UL103 stop codon (Table 2).
Induction of the lambda RED recombinase in SW105 cells harboring pAD/Cre and the
gene cassette lead to homologous recombination followed by selection of transformed
colonies on LB-plates containing kanamycin. Single colonies were screened by BAC
digestion and PCR.
To construct the scarless UL103-V5-His or UL103-BioID mutants, the GalK/kan
cassette was replaced by homologous recombination with another cassette containing
V5-His or BioID and the homologous ends described above (Table 2). SW105 cells
carrying UL103 with the replacement cassette were negatively selected for on 2-deoxygalactose (DOG) minimal plates. Galactose negative colonies were streaked on
MacConkey agar plates supplemented with chloramphenicol and galactose. Nonfermenting colonies were picked and screened by BAC digestion, PCR, and open
reading frame sequence analysis.
Co-Immunoprecipitation (co-IP).

Cells (approximately 3.0x107) were either

transfected with 30 µg of plasmid or inoculated at an MOI of 0.1. Transfected cells were
harvested

after

48

hr,

and

infected

cells

were

harvested

5

dpi

using

radioimmunoprecipitation assay (RIPA) buffer (10 mM HEPES [pH 7.4], 1% sodium
deoxycholate, 1X protease inhibitors [Roche, Indianapolis, IN], 150 mM NaCl, 1%
Nonidet P-40, 0.1% SDS). Protein was extracted by passing the lysate through a 27
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gauge needle 10 times, centrifuging at 13,000 rpm for 10 min, and collecting the
supernatant. Antibodies were conjugated to the beads by mixing 20 µl of protein A/G
Plus Agarose (Santa Cruz Biotechnology, Dallas, Texas) and 1 µg of antibody in 0.5 ml
of PBS at 4°C overnight. Antibody-bead complexes were washed twice in PBS and then
incubated with cell lysates overnight at 4°C in a tube rotator. Non-specific interactions
were stripped from the immunocomplex by washing three times with RIPA buffer. For
mass spectrometry analysis, beads were spun at 2000xg and resuspended in 50 µl of
50 mM ammonium bicarbonate. For binding partner verification, immunocomplexes
were washed with PBS, and the pellet was resuspended in 30 µl of 2X Laemmli sample
buffer for immunoblot analysis.
BioID. Transfected and infected cells were incubated with 50 µM biotin 24 hours
prior to harvesting. Cells lysed as described above were incubated at 4°C overnight with
500 µl of streptavidin conjugated to magnetic beads (New England Biolabs, Ipswich,
MA). Beads were washed once in 1.5 ml of wash buffer 1 (2% SDS in dH2O), once with
wash buffer 2 (0.1% deoxycholate, 1% Triton X-100, 500 mM NaCl, 1 mM EDTA, and
50 mM Hepes, pH 7.5), once with wash buffer 3 (250 mM LiCl, 0.5% NP-40, 0.5%
deoxycholate, 1 mM EDTA, and 10 mM Tris, pH 8.1), and then twice with wash buffer 4
(50 mM Tris, pH 7.4, and 50 mM NaCl). To evaluate sample integrity, 10% of the total
was retained for immunoblots. The remaining beads were spun at 2000xg and
resuspended in 50 µl of 50 mM ammonium bicarbonate for mass spectrometry.
Mass spectrometry. Samples were digested overnight using sequencing-grade
trypsin (Promega) in 25 mM ammonium bicarbonate and 10% acetonitrile. The resulting
peptides were separated by reverse phase chromatography (Acclaim PepMap100 C18
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column, Thermo Scientific), followed by ionization with the Nanospray Flex Ion Source
(Thermo Scientific), and introduced into an Orbitrap FusionTribrid mass spectrometer
(Thermo Scientific). Primary data analysis was done using Proteome Discoverer 1.4
(Thermo), which incorporated the Mascot (Matrix Science) algorithm. Mascot searched
the SwissProt_2014_06 and UniProt_Hum_Compl_All database for viral and cellular
proteins respectively. Secondary analysis was performed with Scaffold 4.3.4 (Proteome
Software) set to a minimum protein identification probability of ≥99% and 2 cellular or 3
viral unique peptides at ≥99% minimum peptide identification probability. Proteins
identified by Scaffold were normalized by size using the normalized spectral abundance
factor (NSAF) (131). Non-specific cellular interactions were filtered out using the
contaminant repository for affinity purification (CRAPome) (132).
Cell Fractionation. HFFs were collected and pelleted in ice cold PBS. Following
pellet resuspension in 900 µl of mild lysis buffer (0.1% NP40 in PBS), 300 µl were
removed as whole cell lysate. Remaining cell lysate was centrifuged for 10 seconds.
300 µl of the supernatant was removed as the cytoplasmic fraction, while the pellet was
washed in 1 ml of lysis buffer followed by another 10 seconds spin to pellet the nuclear
fraction. The nuclear pellet was resuspended in 180 µl of 1X SDS-Laemmli buffer.
Whole cell lysates and nuclear fractions were sonicated prior to immunoblots.
Immunoblots. Protein was quantified by bicinchoninic acid (BCA) assay (Pierce
Biotechnology, Rockford, IL). For cell lysates, 50 µg of protein was solubilized in 2X
SDS-Laemmli buffer followed by SDS-PAGE. Separated proteins were transferred to
nitrocellulose membranes (Whatman, Florham Park, NJ), probed with primary
antibodies, and then reacted with HRP-conjugated goat anti-mouse/rabbit IgG
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secondary antibodies (Thermo Scientific, Rockford, IL). Reactions were detected with
the Supersignal West Pico Chemiluminescent substrate (Bio-Rad, Hercules CA) on
autoradiography film (GE Healthcare, Pittsburgh, PA). Antibodies are listed in Table 3.
Immunofluorescence assays (IFA). HFFs were seeded at 80% confluency one
day prior to infection on 0.2% gelatin-coated 8-well glass chamber slides (Thermo
Fisher Scientific, Waltham, MA). The following day, cells were infected at an MOI of 0.1
and then fixed in paraformaldehyde and stained at 120 hpi as previously described
(129). Primary antibodies are listed in Table 3.

Fluor-tagged secondary antibodies

(Alexa Fluor 488-conjugated goat anti-rabbit IgG and Alexa Fluor 568-conjugated goat
anti-mouse IgG) were from Life Technologies (Grand Island, NY). Mounting was done
with Vectashield containing DAPI (4’,6-diamidino-2-phenylindole) (Vector Laboratories
Inc., CA). Imaging was done on a Nikon E800 fluorescence microscope and a Leica
TCS SP5 laser scanning confocal microscope.
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Results
Experimental design. Affinity purification followed by mass-spectrometry can
be used to identify proteins pulled-down by a bait protein. The proteins identified can be
true interacting partners, but false positives are common, arising due to reasons that
can include non-specific interactions with the beads, antibody, protein tag, and sticky or
highly abundant proteins.

To increase the likelihood of identifying biologically

meaningful interactions, we limited confounding by false positives through the use of
two independent methods of affinity purification: co-immunoprecipitation (co-IP) and
proximity labeled biotinylation (BioID). Co-IP detects proteins that strongly interact with
the bait protein, while the BioID system uses BirA*, a promiscuous biotin ligase that
biotinylates proteins within ~10 nm of the tagged protein (130). Each method uses
different beads, antibodies, tags, and binding/elution conditions. The differences in
these complementary methods provide internal controls that reduce the number of false
positives, while proteins highly enriched in both approaches are more likely to be
specific.
As shown in Table 4, experiments involved plasmids (p) and recombinant viruses
(v) with tags fused to pUL103. Plasmids included one construct that expresses the BirA*
protein alone, one with BirA* fused to the pUL103 N-terminus (BioID-pUL103(p)), and
one in which the V5-His tag was added to the C-terminus of pUL103 (UL103-V5-His(p)).
Two recombinant viruses were also used, in which the tags were attached to the Cterminus of pUL103 (UL103-BioID(v) and UL103-V5-His(v)). For infection experiments,
we inoculated cells at an MOI of 0.1 with either UL103-V5-His(v) or UL103-BioID(v) and
harvested the cells 5 days post infection. A low MOI infection allows simultaneous
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analysis of cells at multiple stages of infection, giving us a broad overview of the viral
and cellular proteins that interact with pUL103.
Collectively, these constructs and conditions enable identification of interactions
of pUL103 with cellular proteins in the absence of other viral proteins, with HCMV
proteins in infected cells, with cellular proteins in infected cells, and with cellular proteins
enhanced during infection.
Effect of tags on virus replication, expression, and localization of pUL103.
To determine if the affinity tags influenced the localization or activity of pUL103 we
conducted immunofluorescence and virus replication plaque assays. In transfected
cells, UL103-V5-His(p) and BioID-UL103(p) were abundant in perinuclear regions that
correspond to ER and Golgi structures (Fig. 15A), while BioID(p) alone was dispersed
diffusely throughout the cell cytoplasm (data not shown). During infection, UL103-V5His(v) and UL103-BioID(v) localized to the assembly compartment, consistent with
previous reports (Fig. 15A) (58, 129). In multi-step growth experiments, UL103-BioID(v)
produced titers similar to the parent, while UL103-V5-His(v) replication was delayed,
taking 6 days to reach parental levels (Fig. 15B). Our previous results using an FKBP
tag also showed a lag in extracellular virus production, suggesting that some tags at the
extreme C-terminus of pUL103 perturb virion production at earlier times after infection
(129). Neither tag had a discernable effect on pUL103 localization or production of
infectious progeny at late stages of viral replication.
Viral proteins identified by AP-MS. Mass spectrometry returned 5566 total
viral spectral hits, which correspond to 49 HCMV proteins using co-IP and 47 proteins
with BioID (outlined in Fig. 16A). Altogether, 53 viral proteins were identified, which
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indicates high overlap using both methods. Larger proteins tend to generate higher
spectral counts than smaller proteins, so we used the normalized spectral abundance
factor (NSAF) to normalize the HCMV proteins based on size. To determine the most
significant interactions, the HCMV proteins displaying an NSAF greater than 0.5 were
plotted on a UL103-BioID vs UL103-V5-His graph (Fig. 16B). The highest NSAF values
were seen for pp65 (21.6 UL103-BioID and 23.4 UL103-V5-His), but pp65 was also
pulled down in untagged AD169 control lanes indicating a non-specific interaction (data
not shown). The second highest NSAF value for UL103-V5-His was pUL103
(NSAF=13.25), demonstrating sufficient immunoprecipitation of the pUL103-V5-His
protein with the V5 antibody. The tegument hub protein, pUL25 was also highly
abundant in both approaches (6.7 UL103-BioID and 4.0 UL103-V5-His), but lack of a
pUL25 specific antibody prohibited further verification. Other proteins enriched were
pUL44, pUL112/113, pUL84, pUL71, pUL50, pUL45, pUL86, IE2, pUL34, pUL47, and
pUL56. The identification of pUL71 by our pull-downs as well as Fischer and Mertens in
transfected cells, provides validity to our dual method approach and evidence that
pUL103 interacts with pUL71 during infection (70). In addition, Roller and Fetters
showed that the homologues of pUL103 and pUL71 (HSV pUL7 and pUL51) form a
complex in HSV1 infected cells (88).
Verification of interactions with viral proteins. We detected many previously
unidentified pUL103 viral binding partners (Fig. 16B). The properties of the highest
scoring viral proteins revealed many to be DNA associated (pUL34, IE2, pUL44, pUL84,
etc.). This was surprising, since our lab and others have shown pUL103
immunofluorescence staining to be strictly cytoplasmic in infected cells (58, 129) (Fig.
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15A). Nonetheless, the HSV1 and HSV2 homologs of pUL103 (HSV pUL7) can be
present in nuclei (82, 89). To assess the nuclear presence of pUL103 we performed
three-dimensional confocal microscopy on HCMV infected cells. Although much less
intense than the cytoplasmic fluorescence, in central slices of the z-series
(approximately equidistant from apical and basal surfaces), weak, but unambiguous
nuclear staining for pUL103 was present in nuclei (Fig. 17A). We also performed cellular
fractionation followed by western blots and found that pUL103 is present in the nuclear
fractions of cells (Fig. 17B).
We employed immunoprecipitation and immunoblotting to verify interactions of
pUL103 with three of the DNA associated viral proteins (IE2, UL34, and UL44). IE2 and
pUL34 were verified by pull-downs with a V5 antibody followed by immunoblotting. Each
blot showed a band in the UL103-V5-His IP lane, but not in the parent or control lanes
(Figs. 17C and 17D). pUL44 is approximately 46 kDa and is obscured by the 50 kDa
heavy chain antibody band. Because of this, pUL103-V5-His was immunoprecipitated
with a pUL44 antibody and then probed with anti-His. There was a clear band in the
UL103-V5-His (Fig. 17C, lane 3) that co-migrates with pUL103 in the total cell lysates
(Fig. 17C, lane 6). These results provide evidence for the specificity obtained by
merging results obtained with two independent affinity-based pull-down approaches,
and revealed novel interactions of pUL103 with IE2, pUL34 and pUL44.
Interactions of pUL103 with cellular proteins.

We used the dual affinity

purification approach to identify the binding partners of pUL103 in transfected and
HCMV infected cells. Mass spectrometry detected a total of 2953 cellular proteins pulled
down by both methods. As mentioned previously, the NSAF formula was applied for
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spectral count normalization. Our initial mass spectrometry dataset included proteins
(tubulins, actins, ribosomal, and mitochondrial) that were abundant in the BioIDUL103(p) control or had high CRAPome scores, indicating non-specific interactions. To
eliminate background, we only considered proteins that had a UL103-BioID(v) NSAF
value higher than the NSAF of the BioID(p) control, and a CRAPome score lower than
100. We utilized two methods of analysis; NSAF to identify all the cellular protein
interactions (Fig. 18A) and NSAF fold-change of infected cells versus uninfected cells to
detect interactions enhanced during infection (Fig. 18C). Stringent cutoffs of 3 and 2
were used for NSAF and for NSAF fold-change, respectively, to identify pUL103 binding
partners that are potentially of biological significance (Fig. 18B and 18D). A total of 13
cellular proteins met these criteria, with 6 being shared between both analyses (Table 5
and Figs. 18A and 18C).
Among the highly enriched proteins are several involved in innate immune
responses (IFI16, STAT1, ISG15, MYD88, and IFIT1). All of these antiviral proteins had
low NSAF scores or were undetected in transfected cells, thus the interactions might be
attributed to elevated protein expression in infected cells. However, the mRNA levels of
IFI16 decreased by 71% and 62% in fibroblasts infected for 96 hours with HCMV strains
Towne and AD169 (133); a similar decrease is evident in immunoblots of infected cell
lysates (Fig. 19A). Importantly, the IFI16 interaction was verified by forward and reverse
co-IP, suggesting a novel role for pUL103 in the regulation of innate immune signaling
during infection (Fig. 19A).
Another category of proteins identified in these analyses includes proteins
involved in formation and trafficking of vesicle (MYO1C, PDCD6IP, and COPB1), which
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may interact with pUL103 during virion envelopment and egress. Pulldowns in
transfected and infected cells confirmed the binding of pUL103 to the ESCRTassociated protein, ALIX (Fig. 19B). Interestingly, amino acid motif analysis of pUL103
revealed two potential “late” or “L” domains that bind ALIX at the C-terminus (Fig. 20A).
ALIX binding domains are well-characterized motifs present in retrovirus gag proteins
that are sites of interaction with ALIX important for virion budding at the plasma
membrane (reviewed in (134)). These results led us to further explore the pUL103-ALIX
interaction.
Mutational analysis of ALIX binding motifs in uninfected cells. The amino
acids YPNL at position 230 to 233 in pUL103 represent a type 1 late domain (134). The
YPNL present in pUL103 corresponds to the YPXnL ALIX binding motif (X is any residue
and n can range from 1 to 3). In non-normalized transfection experiments with single
and multiple amino acid substitution of the YPNL motif had little effect on pUL103-ALIX
interaction (Fig. 20B).
Fifteen amino acids upstream of YPNL, is a sequence, GWPVGLGLL, that has
properties that suggest it might serve as an ALIX site. The high similarity between
tryptophan and tyrosine allow them to sometimes be interchanged, as seen in
SIVwrcPbb Gag p6, in which the YPXL motif is replaced by WPXL (135). The
GWPVGLGLL sequence thus conforms to both type 1(YPXnL) and type 3 (ΦYXnΦXnL)
late domain motifs. In experiments in which levels of pUL103 were normalized relative
to GAPDH, mutation of either of the putative pUL103 late domains led to at least 50%
reduction in ALIX that was pulled down in uninfected cells (Fig. 19C). These results are
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consistent with pUL103 containing two motifs together are important for its interaction
with ALIX.
Influence of pUL103 on ALIX localization. Given the involvement of ALIX in
vesiculation events similar to those associated with secondary envelopment, we
examined ALIX localization during infection. By IFA, ALIX was diffusely distributed
throughout the cytoplasm of uninfected cells, but strongly localized to the cVAC at late
times post infection (Fig. 21A). To assess the location of ALIX in the absence of
pUL103, we used a UL103-FKBP-V5 virus that contains a regulatable destabilization
domain attached to UL103 (129). In the presence of Shield-1, pUL103 was stabilized
and abundant in the cVAC along with ALIX (Fig. 22A). Removal of Shield-1 reduced the
amount of pUL103 and ALIX in the assembly complex by 34% and 56% respectively
(3D quantification of at least 14 cells per condition). The effect on ALIX was not due to
differential ALIX expression, as immunoblots showed that levels of ALIX were similar in
mock infected cells and in cells infected with either the parental or V5-His-tagged UL103
viruses, and regardless of whether the UL103-FKBP-V5 virus was treated with Shield-1
(Fig. 21B). These results demonstrate that HCMV infection results in pUL103-regulated
localization of ALIX to the cVAC.
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Discussion
HCMV pUL103 is a conserved herpesvirus tegument protein that is involved in
several processes, including cell-to-cell spread, cVAC biogenesis, and virion
envelopment and egress. We identified its interaction partners to provide novel insights
into its molecular functions and biological roles. Several pUL103 binding partners were
identified in transfection and yeast two-hybrid systems, but none have been
characterized in the context of infection (70, 120). HCMV infection induces profound
changes in host cells, altering the localization, production, and function of cellular
proteins. In addition, in the absence of infection, interactions among viral proteins, as
well as interactions of viral proteins with cellular proteins (e.g., antiviral proteins) do not
occur. To address these gaps, we infected cells with recombinant viruses that express
forms of pUL103 that were tagged to enable independent forms of pull-downs (co-IP
and BioID). This was followed by mass spectrometry to identify interacting partners. By
restricting our analysis to interactions that scored highly in both of the complimentary
methods, we increased the likelihood of selecting specific, high-value biologically
relevant interactions worthy of further study, while limiting the number of false positives
and incidental interactions. The set of viral and cellular binding partners we identified
for pUL103 suggest that it, and possibly its homologs in other herpesviruses, interact
with nuclear proteins that bind DNA, and play roles in the regulation of antiviral
responses and in formation, transport, and targeting of intracellular vesicles. The latter
activities may be important during during cVAC biogenesis, and subsequently during
secondary envelopment and egress.
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Interactions of pUL103 with other HCMV proteins. The viral proteins that met
our screening criteria belong to several distinct functional categories, including
tegument proteins, DNA-binding proteins, and capsid and nuclear egress proteins.
pUL103-pUL71 was previously shown to interact outside the context of infection in cotransfection and bimolecular fluorescence complementation experiments (70), and
interactions between the HSV homologs (pUL7 and UL51) of these proteins were
detected in infected cells (88). Our detection of this interaction provides validation for
our dual pulldown approach.
Of the interactions that scored highly in both the V5 and BioID experiments,
follow-up pull-down experiments were performed with antibodies against pUL34, pUL44,
and IE2; in each instance, the interactions were detected only in cells infected with the
UL103-V5-His virus, and not in mock infected cells or cells infected with untagged
parental virus. These results provide further evidence that the interactions
characterized by high NSAF scores in both the V5- and BioID-based proteomic
analyses are sufficiently specific to justify follow-up studies.
The most prominent interaction with dual high NSAF scores was observed
between pUL103 and the HCMV tegument protein pUL25. pUL25 is expressed at late
times post infection, strongly localizes to the cVAC, and is incorporated into the three
major types of virus particles: mature virions, noninfectious enveloped particles, and
dense bodies (136, 137). The reported interactions of pUL25 with several other
tegument proteins suggests it serves as an organizing hub for incorporating viral
proteins into enveloped particles (120). Further analysis of the pUL103-pUL25
interaction is warranted.
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We did not detect the previously described interactions between pUL103 and
HCMV pUL22A and pUL48N, which were identified in a yeast two-hybrid system but not
verified by co-IP in transfected cells (120). In yeast cells, pUL103 may lack
posttranslational modification(s) or have alternative folding that exposes or creates
artificial binding sites. While we acknowledge their limitations, tagged recombinant
viruses can provide useful representations of protein-protein interactions during
infection. The specificity of such methods can be enhanced by screening on the basis of
dual high positivity using co-IP and Bio-ID methods.
Nuclear pUL103. Identification of five viral DNA associated proteins with dual
NSAF values above 0.5 (Fig. 16B) and the co-IP verification of three of these (pUL34,
pUL44, and IE2), suggests a nuclear role for pUL103. This was unexpected given that
pUL103 appears to be strictly cytoplasmic by IFA in HCMV infected cells. Only after
substantially increased exposure times were we able to detect a faint but discernable
pUL103 signal in nuclei (Fig. 17A). Immunoblots of fractionated cells confirmed the
presence of pUL103 in the nuclear fraction. Nuclear pUL103 has also been described
for the HSV homolog (pUL7), in which IFA and transmission immunoelectron
microscopy analysis detected pUL7 in infected cell nuclei (88, 89). The function of
nuclear pUL103 is unknown, but may involve a conserved domain, present in the
pUL103 homologs of all members of the herpesviridae. The conserved domain is
homologous with a segment of DNA topoisomerase III of Schizosaccharomyces pombe;
this protein releases supercoil tension that is introduced during DNA replication and
transcription (89, 138). The presence of this conserved domain, in conjunction with its
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observed nuclear localization and interaction with HCMV DNA associated proteins
suggests a heretofore undefined role for pUL103 in nuclear events.
Interactions of pUL103 with cellular proteins. Our interest at this stage is to
identify interactions unique to pUL103 that are more likely to be of true biological
significance. Because of this, we applied the stringent screening criteria, described in
the Results section and in Fig. 16A, understanding that we likely excluded some true
interactions. For instance, HSV pUL7 can pull-down the mitochondrial protein, ANT2
(82). We found a dual high scoring interaction between ANT2 and pUL103 in
transfected and in infected cells, but because ANT2 has a CRAPome score of 223, it
did not pass our screening filter. Even though the interaction might be biologically
meaningful, we did not pursue it here.
Most of the proteins that passed our screening criteria are involved in innate
antiviral responses and vesicle formation/trafficking (Fig. 18A). A cellular protein from
each category was verified in reciprocal pull-down experiments, providing evidence that
these represent true interactions.
A novel role for pUL103 in innate immunity? A possible role for pUL103 in
regulation of innate immunity is difficult to evaluate in uninfected cells. With the
exception of STAT1, none of the antiviral interaction partners were detected in our
transfection experiments. In infected cells, the presence of pathogen-associated
molecular patterns (PAMPs) activates the antiviral response. Relocalization, increased
expression, or phosphorylation can lead to interactions with viral binding partners. We
identified four antiviral proteins that displayed dual high NSAF scores and verified the
interaction with IFI16 by reciprocal co-IP. The abundance of antiviral proteins detected
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demonstrates that pUL103 is capable of interacting with and modulating the innate
immune response either directly or indirectly.
We did our proteomic experiments after low moi infections (moi - = 0.1).

In

addition to cells at the late stage of infection, at the time of harvest (5 dpi), the cultures
would have included non-synchronously infected cells at the earliest stages of infection.
We were thus able to sample material from various stages of infection. Virion tegument
proteins are introduced into the host cell immediately upon fusion of the viral and host
cell membranes. The release of tegument proteins pp65 and pp71 into host cells are
known to be critical for subverting the innate immune response and helping to establish
an environment conducive to productive infection (139, 140). pUL103 is a virion
associated tegument protein and may have a similar function when engaging antiviral
proteins (54). In addition, virion associated and newly synthesized pUL103 could
interact with antiviral proteins to facilitate cVAC biogenesis. Recent work by Xie and
colleagues showed that HCMV makes use of interferon-induced transmembrane
proteins (IFITMs) for cVAC assembly and virion production (71). The biological role of
the pUL103 interaction with antiviral proteins is being assessed.
Potential roles for pUL103 in biogenesis and trafficking of intracellular
vesicles.

Identification of three proteins (COPB1, MYO1C, and ALIX) involved in

formation and trafficking of vesicles suggests a connection to the known role of pUL103
in virion envelopment and egress. The COPB1 mediates Golgi fragmentation during the
M-phase of the cell cycle and retrograde transport from the Golgi to the ER (141, 142).
MYO1C is involved in trafficking GLUT4 to the plasma membrane, and participates in
lipid raft organization (143-145). These cellular proteins have functions that encompass
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activities of the sort that would be involved in cVAC biogenesis and trafficking of virions
to the cytoplasmic membrane, a subject for future study.
The specificity of the pUL103-ALIX interaction was demonstrated by a
combination of dual high NSAF scores using both proteomic approaches, a low
CRAPome score for ALIX, NSAF scores higher for pUL103 pull-downs than for free
BioID, pull-downs in cells transfected with pUL103-V5-His, and positive pull-downs in
cells infected with UL103-V5-His(v) but not with the untagged parental virus. Proteins
that bind to ALIX typically interact via ALIX-specific late domains that are important for
virion production in many RNA and DNA viruses (146-150). Late domains in retrovirus
gag proteins can bind the V domain of ALIX to facilitate viral budding at the cell
membrane (reviewed in (134, 149, 150)). For DNA viruses, vaccinia viruses use an
ALIX binding domain for extracellular virion production, and Epstein-Barr virus, a
gammaherpesvirus, exploits ALIX for vesicle formation and nuclear egress of capsids
(146, 148). The use of ALIX and ESCRT machinery is thus a common theme for virion
production for many viruses.
By sequence analysis, we identified two adjacent ALIX-binding motifs in pUL103,
one that conforms to canonical Type1 and Type 3 motifs, and one that matches the
Type 1 motif (Fig. 20A).

We evaluated mutations in these motifs in pull-down

experiments, and found that changes in the Type 1 motif had little effect by themselves,
while deletion of the Type1 or 3 motif or substitution of five critical residues with
alanines led to >60% reduction in the amount of ALIX pulled down by pUL103-V5-His.
Our identification of two adjacent ALIX binding domains in HCMV pUL103 and
the strong infection and pUL103 influenced or induced localization of ALIX to the cVAC
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during infection suggest involvement of ALIX in HCMV envelopment and egress,
perhaps during secondary envelopment. However, siRNA knockdown and dominant
negative versions of ALIX had no effect on HCMV virion production (48, 78). This raises
the possibility that HCMV employs redundant ESCRT-related pathways during the late
stages of virion biogenesis. Recombinant viruses with altered pUL103 ALIX binding
domains are under construction to enable elucidation of the role of the pUL103-ALIX
interaction during infection.
A major challenge for identification of interacting partners is the abundance of
false-positives that are typically observed. To address this, we employed parallel
analysis of interacting partners pulled down using two affinity based methods (V5-His
and BioID). By coupling dual high NSAF cutoffs with other stringent selection criteria we
effectively screened for high value interactions. Detection of the previously identified
pUL71 interaction, and verification of pUL44, IFI16, and ALIX interactions by reverse coIP, indicates our screening process selected for biologically plausible interactions. The
collection of viral and cellular proteins identified provides novel insights into the
biological functions of pUL103 and its respective homologs. This provides a robust
foundation for future studies.
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early late

early

early late

pseudorabies virus
(PRV)

bovine herpes virus
1 (BHV-1)

human
cytomegalovirus
(HCMV)

Protein
Kinetics
delayed
early or
early late

herpes simplex
virus 2 (HSV-2)

Virus
herpes simplex
virus 1 (HSV-1)

250

300

266

296

Size
(aa)
296

Nonessential (up to 3.5 logs), decrease in viral
titers, 60% reduction in plaque size, delayed
secondary envelopment and release of dense
bodies and virions

Nonessential, decrease in viral titers (up to 0.5
logs), 60% reduction in plaque size, inefficient
secondary envelopment, and a delay in
neuroinvasion
Nonessential, reduction in viral titers

N/A

Properties
Deletion
Essential or nonessential, decrease in viral
titers (up to 3 logs), 50% reduction in plaque
size

Juxtanuclear with Golgi
markers. Present in mature
virions

Cytoplasmic, not present in
mature virions

N/A

Nuclear and juxtanuclear.
Present in mature virions

Localization
Nuclear and juxtanuclear.
Present in mature virions

Table 7. Properties of HCMV pUL103 and its alphaherpesvirus UL7 homologs

pUL103
pUL22A
pUL48N
pUL71

N/A

N/A

A,B, and C capsids
(weak)

Interactions
ANT2
pUL51 (HCMV pUL71)

(56,
111,
121)

(77)

(71,
78)

(80)

Ref
(70, 73,
79)

75

76
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Table 9. Antibodies used in IFA and immuoblot assays
Antibody Target

Host/isotype, clone

Source, catalog no.

Epitope tag
V5 (14 amino acids)

Mouse monoclonal/IgG2a

Life Technologies, R960-25

His (6 amino acids)

Rabbit polyclonal

Rockland 600-401-382

GAPDH (36 kDa)

Mouse monoclonal/IgG1, clone GA1R

Thermo Scientific, MA5-15738

GM130 (130 kDa)

Mouse monoclonal/IgG1(κ), clone 35/GM130

BD Biosciences, 610822

EEA1 (180 kDa)

Rabbit polyclonal

Abcam, ab2900

IFI16 (85-95 kDa)

Mouse monoclonal/IgG1, clone 1G7

Santa Cruz, sc-8023

Myo18A (230,190 kDa)

Mouse monoclonal/IgG1, clone H-10

Santa Cruz, sc-365328

ALIX (96 kDa)

Rabbit polyclonal

Abcam, ab76608

Cellular

HCMV
IE1 and IE2 (IE1, 72 kDa;IE2, 86 kDa)

Mouse monoclonal/IgG1(κ), clone CH160

Virusys, P1215

IE2 (86 kDa)

Mouse monoclonal, clone 8B1.2

Chemicon (millipore), MAB810

pUL44 (CMV ICP36), 46 kDa

Mouse monoclonal/IgG1(κ), clone 10D8

Virusys, CA006-100

UL34-R4

Rabbit polyclonal

Bonita Biegalke (Ohio
University)
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Table 10. Constructs and experiment conditions
Constructs

Condition

Affinity ligand

Beads

BioID(p)

Transfected

Streptavidin

Magnetic

BioID-UL103(p)

Transfected

Streptavidin

Magnetic

UL103-BioID(v)
UL103-V5-His(p)

Transfected
Infected

Streptavidin
V5

Magnetic
Agarose A/G

UL103-V5-His(v)

Infected

V5

Agarose A/G

COPB1

PDCD6IP (ALIX)

SEC61A1

IFIT1

MYO1C

Microtubule assembly
Collagen biosynthesis and folding

TUBB3
SERPINH1
(HSP70)
STAT1
ISG15
IFI16
Antiviral transcription activator
Ubiquitin-like protein with antiviral activity
Viral DNA sensor that triggers innate immune
response
Intracellular vesicle transport. Nuclear isoform
functions in transcription initiation
RNA-binding protein that inhibits viral replication and
translation initiation
Associated with ER ribosomes for assembly of
membrane and secretory proteins
Associated with ESCRT machinery sorting of protein
cargo into MVBs
Mediates retrograde Golgi-to-ER transport

Property

Gene

3.0, 3.6

3.6, 5.9

3.9, 3.5

4.2, 3.1

4.7, 9.3

6.2, 4.6
6.0, 3.1
4.9, 21.5

0.6, 1.9

0.7, 3.3

0.8, 2.5

4.2, 3.1

3.2, 12.6

3.9, 8.9
6.0, 3.1
4.9, 21.5

NSAF FC
V5, BioID
1.1, 1.3
3.1, 6.1

Infected
NSAF
V5, BioID
19.1, 13.5
10.6, 4.8

Table 11. Properties of the cellular proteins meeting selection criteria

1.2

1.9

1.4

0.0

0.9

0.9
0.0
0.4

9.5
0.3

NSAF BioID(p)

Transfected

92

55

28

4

66

23
5
9

CRAPome
N/A
78

79
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Figure 15. The effect of tagged pUL103 on localization and viral growth. (A) HFFs were
either transfected (p) for 48 hours or infected (v) at an MOI of 0.2 for 120 hours, then analyzed
by fluorescence microscopy. pUL103 was visualized using a V5 antibody against the V5-His
epitope or a myc antibody targeting the BioID tag. (B) Replication of UL103-V5-His and UL103BioID recombinant viruses were evaluated by multi-step growth curves (MOI=0.1). Virus titers
were performed in triplicate.
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Figure 16. Experimental scheme and graphical representation of enriched HCMV
proteins. (A) HFFs were infected for 120 h at an MOI of 0.1 with UL103-V5-His(v) or
UL103-BioID(v) and immunocomplexes were pulled-down with antibodies to V5 or biotin
respectively. Mass spectrometry spectral counts were normalized based on size using
the normalized spectral abundance factor (NSAF) formula. (B) Scatter plot of viral
protein NSAFs from co-immunoprecipitation and proximity labeled biotinylation
experiments. The dotted line separates the viral proteins with an NSAF > 0.5 (colored)
from those less enriched (gray). Asterisk (*) indicates a known interaction. (C) Bar graph
of all the viral proteins identified at increasing NSAF thresholds. The stripes indicate
proteins shared by both methods.
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Figure 17. Localization of pUL103 in infected cells and co-immunoprecipitation
verification of viral proteins. (A and B) HFFs were infected with UL103-V5-His(v) for
96 h at an MOI of 0.1 and probed with anti-V5 antibody. (A) The pUL103-V5-His tagged
protein was analyzed by confocal microscopy. The center slice of a z-stack is shown
with the nuclei outlined using ImageJ. (B) Cellular fractionation of infected cells using
antibodies against UL44 and GAPDH to determine nuclear (N) and cytoplasmic (CY)
fractions respectively. (C and D) Pull-downs were performed with anti-UL44 or anti-V5
on HFFs infected for 120 h at an MOI of 0.1. The immunoprecipitating antibody (IP) and
the probing antibody (IB) are listed to the left of each blot. Immunoblots were probed
with antibodies against His tagged UL103, IE1/2, and UL34
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Figure 18. Charts of the NSAF and NSAF fold change of cellular protein
interactions. (A) After filtering out non-specific interactions, the cellular NSAF of the of
UL103-V5-His(v) and UL103-BioID(v) was plotted against each other. The function of
the most enriched interactions (NSAF >3) are shown. (C) NSAF fold change selects for
cellular interactions enhanced during infection. Fold changes greater than 2 highlights
multiple antiviral proteins. (B and D) Charts showing all the cellular proteins at
increasing cutoff values. The stripes indicate proteins shared by both methods.
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Figure 19. Co-immunoprecipitation verification of IFI16 and ALIX interactions. (A)
HFFs were infected for 120 h at an MOI of 0.1 and affinity purification was conducted on
the left three lanes while the right three lanes contain protein from cell lysates. The
immunoprecipitating antibody (IP) and the probing antibody (IB) are listed to the left of
each blot. pUL103 was purified with IFI16 in reciprocal pull down assays. (B) Affinity
purification of pUL103 using a V5 antibody verified the interaction with ALIX in
transfected and infected cells.
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Figure 20. pUL103 amino acid sequence schematic and mutational analysis of late
domains. (A) Map of HCMV pUL103 gene depicting a herpesvirus conserved region
(GFX8EDX12R), along with HCMV specific helicase and late domains. (B and C) Coimmunoprecipitations of pUL103 using a V5 antibody in transfected cells. (B) Alanine
substitutions within the ALIX motif had little to no effect on the pUL103-ALIX interaction.
(C) Alteration of the first or second ALIX binding motif reduced the quantity of ALIX
pulled down with pUL103. (D) The quantity of ALIX immunoprecipitated per condition
was measured by densitometry and divided by normalized pUL103. The amount of
pUL103 produced was normalized by taking the ratio of GAPDH to pUL103.
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Figure 21. ALIX redistribution during infection. (A and B) ALIX localization and
proteins levels were detected in uninfected and infected HFFs (MOI of 0.1, 120 hpi) by
IFA and immunoblot. (A) Infection enhances ALIX staining which overlaps cVAC
markers. (B) The protein levels ALIX were unchanged with each condition.
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Figure 22. ALIX redistribution involves pUL103. (A) The localization of ALIX during
pUL103 regulation by the Shield-1 ligand. (B) 3D quantitation of ALIX mean
fluorescence intensity in the cVAC relative to the parent (measured using ImageJ). A
significant change was seen only in the presence and absence of pUL103. (C) The
same cVAC area was used for 3D quantitation of pUL103 by mean fluorescence
intensity.

88

Chapter Four
Conclusions and Discussion
Human cytomegalovirus (HCMV) infection has multiple effects on host cells,
including remodeling the cytoplasm to form the cytoplasmic virion assembly complex
(cVAC), the site of final virion assembly. The HCMV genes specifically responsible for
initiating and regulating cVAC biogenesis have not been defined. Our work set out to
determine which HCMV genes are involved in this process. Previous work in our lab
described the three dimensional structure of the cVAC using cellular markers against
Golgi, trans-Golgi and early endosomes components. These cellular markers were used
as indications of proper cVAC development. An siRNA screen targeting 26 early-late
and late genes identified three HCMV genes (UL48, UL94, and UL103) whose silencing
had major effects on cVAC development. To ensure the protein product of these genes
is specifically involved; we created two recombinant viruses with a protein
destabilization tag attached to UL48 or UL103. Degradation of either protein resulted in
the disrupted cVAC assembly, validating the siRNA results. The set of viral genes
identified is by no means all-encompassing as other immediate early or early genes
were not included in our analysis.
It is important to note, that all three proteins involved in cVAC biogenesis are
tegument proteins incorporated into mature virions (54). Tegument proteins introduced
into host cells upon entry may facilitate cVAC development, yet whether these proteins
play a role during early or late stages of infection has yet to be addressed. The
incomplete degradation of these proteins using the FKBP destabilization domain has
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prevented these types of analyses. However, the partial degradation of pUL48 and
pUL103 is sufficient to disrupt cVAC formation, suggesting that wild-type expression
levels are necessary for efficient virion production.
In addition to cVAC biogenesis, pUL103 is a highly conserved, multifunctional
herpesvirus tegument protein involved in several processes, including cell-to-cell spread
and virion envelopment and egress. To further understand the mechanisms of action
and predict additional functions of pUL103, we sought to identify its interaction partners.
To do so, we employed two complementary methods, co-immunoprecipitation (co-IP)
and BioID, to detect viral and cellular proteins that interact with pUL103 in uninfected
and HCMV infected cells. Our approach identified a multitude of pUL103 binding
partners. To identify interactions of potentially high value, we selected for interactions
highly abundant in both approaches and applied stringent selection criteria. The viral
and cellular proteins that passed our selection criteria are associated with DNA, the
antiviral response, and the biogenesis and transport of cytoplasmic vesicles.
Analysis of some of these interactions expanded our current understanding of the
pUL103 multifunctional repertoire; we detected HCMV pUL103 in nuclei of infected
cells, identified two functional ALIX binding domains, and established a role for pUL103
in ALIX localization during infection. This provides novel insights to the biological
functions of pUL103 that may also be exercised by its homologous herpesvirus
counterparts.
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Human cytomegalovirus (HCMV) is a large double-stranded DNA virus that
causes severe disease in newborns and immunocompromised patients. During
infection, HCMV is able to reconfigure the host cell machinery to establish a virus
producing factory, termed the cytoplasmic virion assembly complex (cVAC). Generating
drugs that affect cVAC development or function provides an alternative mode of action
for HCMV antivirals that can essentially eliminate virion production. The objective of this
work is aimed at identifying regulators of cVAC biogenesis that may serve as potential
drug targets.
We identified three HCMV genes (UL48, UL94, and UL103) whose silencing or
protein degradation had major effects on cVAC development, including failure to form
the Golgi ring and dispersal of markers of early and recycling endosomes. In addition,
we found that mutant viruses expressing an unstable form of the UL103 protein causes
a reduction in plaque size and the aberrant formation of intracellular virions.
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To help define the mechanisms of action and predict additional functions of
pUL103, we investigated its viral and cellular protein-protein interactions. We applied a
dual method approach, co-immunoprecipitation and proximity biotinylation affinity
purification followed by mass spectrometry to enrich for pUL103 interaction partners in
uninfected and HCMV infected cells. This led to identification of pUL103 in nuclei,
delineation of a novel ALIX binding domain, and a role for pUL103 in ALIX localization in
infected cells.
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